



ALMA MATER STUDIORUM  
UNIVERSITÀ DI BOLOGNA

## ARCHIVIO ISTITUZIONALE DELLA RICERCA

### Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

ESPEN practical guideline: Home parenteral nutrition

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

*Published Version:*

Pironi L., Boeykens K., Bozzetti F., Joly F., Klek S., Lal S., et al. (2023). ESPEN practical guideline: Home parenteral nutrition. CLINICAL NUTRITION, 42(3), 411-430 [10.1016/j.clnu.2022.12.003].

*Availability:*

This version is available at: <https://hdl.handle.net/11585/964689> since: 2024-03-01

*Published:*

DOI: <http://doi.org/10.1016/j.clnu.2022.12.003>

*Terms of use:*

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).  
When citing, please refer to the published version.

(Article begins on next page)

## ESPEN practical guideline: home parenteral nutrition

Loris Pironi <sup>a,b</sup>, Kurt Boeykens <sup>c</sup>, Federico Bozzetti <sup>d</sup>, Francisca Joly <sup>e</sup>, Stanislaw Klek <sup>f</sup>, Simon Lal <sup>g</sup>,  
Marek Lichota <sup>h</sup>, Stefan Mühlebach <sup>i</sup>, Andre Van Gossum <sup>j</sup>, Geert Wanten <sup>k</sup>, Carolyn Wheatley <sup>l</sup>,  
Stephan C. Bischoff <sup>m</sup>

<sup>a</sup> University of Bologna, Department of Medical and Surgical Sciences, Italy

<sup>b</sup> IRCCS AOUBO, Centre for Chronic Intestinal Failure - Clinical Nutrition and Metabolism Unit, Italy

<sup>c</sup> Vitaz Hospital, Nutrition Support Team, Sint-Niklaas, Belgium

<sup>d</sup> Faculty of Medicine, University of Milan, Italy

<sup>e</sup> Beaujon Hospital, APHP, Clichy, University of Paris VII, France

<sup>f</sup> Surgical Oncology Clinic, The Maria Skłodowska-Curie National Cancer Institute, Krakow, Poland

<sup>g</sup> Salford Royal NHS Foundation Trust, Salford, United Kingdom

<sup>h</sup> Intestinal Failure Patients Association "Appetite for Life", Cracow, Poland

<sup>i</sup> Division of Clinical Pharmacy and Epidemiology and Hospital Pharmacy, University of Basel, Basel,  
Switzerland

<sup>j</sup> Hôpital Erasme and Institut Bordet, Brussels, Belgium

<sup>k</sup> Intestinal Failure Unit, Radboud University Medical Centre, Nijmegen, The Netherlands

<sup>l</sup> Support and advocacy group for people on home artificial nutrition (PINNT), United Kingdom

<sup>m</sup> University of Hohenheim, Institute of Nutritional Medicine, Stuttgart, Germany

### Corresponding author

E-mail address: [loris.pironi@unibo.it](mailto:loris.pironi@unibo.it) (L. Pironi)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Abstract**

This guideline will inform physicians, nurses, dieticians, pharmacists, caregivers and other home parenteral nutrition (HPN) providers, as well as healthcare administrators and policy makers, about appropriate and safe HPN provision. This guideline will also inform patients requiring HPN. The guideline is based on previous published guidelines and provides an update of current evidence and expert opinion; it consists of 71 recommendations that address the indications for HPN, central venous access device (CVAD) and infusion pump, infusion catheter and CVAD site care, nutritional admixtures, program monitoring and management. Meta-analyses, systematic reviews and single clinical trials based on clinical questions were searched according to the PICO format. The evidence was evaluated and used to develop clinical recommendations implementing Scottish Intercollegiate Guidelines Network methodology. The guideline was commissioned and financially supported by ESPEN and members of the guideline group were selected by ESPEN.

**Keywords**

Caregiver, Central venous access device, Home parenteral nutrition, Intestinal failure, Management, Monitoring, Multidisciplinary team, Parenteral nutrition admixture, Patient training

**List of abbreviations**

AIO, all-in-one parenteral nutrition admixture; CDC, Center for Disease Control and Prevention; CIF, chronic intestinal failure; CRBSI, catheter-related bloodstream infection; CVAD, central venous access device; CVC, central venous catheter; EN, enteral nutrition; HPN, home parenteral nutrition; NST, nutrition support team; PICC, peripherally inserted central venous catheter; PN, parenteral nutrition; QoL, quality of life; RCT, randomized controlled trial

## Introduction

Parenteral nutrition (PN) is categorized as total (or exclusive) PN, where it meets the patient's nutritional needs in entirety, and as supplemental (partial or complementary) PN, where nutrition is also provided via the oral or enteral route. PN can be administered either in, or outside the hospital setting; the latter defined as home parenteral nutrition (HPN) [1].

HPN is the primary life-saving therapy for patients with chronic intestinal failure (CIF) due to either benign or malignant diseases [2-4]. HPN may also be provided as palliative nutrition to patients in late phases of end-stage diseases [1]. As HPN is sometimes used to prevent or treat malnutrition in patients with a functioning intestine, who decline medical nutrition via the oral/enteral route, HPN and CIF cannot be considered synonymous [2]. Thus, on the basis of underlying gastrointestinal function and disease, in tandem with patient characteristics, four clinical scenarios for the use of HPN can be identified [2-4]: (i) HPN as primary life-saving therapy for a patient with CIF due to benign disease; (ii) HPN for CIF due to malignant diseases, often transiently occurring during curative treatments; (iii) HPN included in a program of palliative care for incurable malignant disease, to avoid death from malnutrition; (iv) HPN used to prevent or treat malnutrition in patients with a functioning intestine, who decline other types of medical nutrition ('no-CIF scenario'). The goal and characteristics of the HPN program, as well as the specific needs of the patient, may differ among the four clinical scenarios.

The first European Society for Clinical Nutrition and Metabolism (ESPEN) guideline on HPN was published in 2009 [3]. It consisted of 26 recommendations, 10 were based on some evidence (grade B recommendations) but 16 were mostly based on expert opinion ('grade C recommendations'). In 2016, ESPEN guidelines for CIF due to benign disease was published, including 11 recommendations on HPN management, 17 on PN formulation and 22 on the prevention and treatment of central

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

venous catheter (CVC)-related complications [4]. The grade of evidence was very low for 31 recommendations, low for 14, moderate for 3 and high for 2, whereas the strength of the recommendations was weak for 18 and strong for 32. Most of the recommendations from both guidelines are still valid, particularly those covering nutritional requirements, metabolic complications and central venous access device (CVAD) management. Other guidelines and standards for HPN have also been provided by scientific societies and government bodies [5-14]; however, a systematic review revealed substantial differences among the recommendations published [10]. Furthermore, the management and provision of HPN differs among countries and among HPN centers within countries [15, 16], although HPN provision by different programs should be homogeneous in order to ensure equity of patient access to an appropriate and safe HPN service.

An updated version of ESPEN guidelines on HPN care was commissioned and finally published in 2020 in order to incorporate new evidence since the publication of the previous ESPEN guidelines, to highlight recommendations on safe HPN administration and to include the patient's perspective [17]. Based on this guideline, the present "ESPEN Practical guideline" comprising practical flow charts was created. The aim of this guideline is to provide recommendations for the appropriate and safe provision of HPN in a short and precise way clinical practice. This guideline does not include recommendations for the patient's nutrient requirements in specific conditions, for which the reader can refer to previous ESPEN guidelines [3, 4, 14].

## Methods

1  
2  
3 The present practical guideline consists of 71 recommendations and five statements and is based  
4  
5  
6 on the European Society for Clinical Nutrition and Metabolism (ESPEN) guideline on home  
7  
8  
9 parenteral nutrition [17]. The original guideline was shortened by focusing the commentaries on the  
10  
11  
12 evidence and literature on which the recommendations are based on. The recommendations were not  
13  
14  
15 changed, but the presentation of the content was transformed into a graphical presentation. The original  
16  
17  
18 guideline was developed according to the standard operating procedure (SOP) for ESPEN guidelines  
19  
20  
21 and consensus papers [18].

22 This SOP is oriented on the methodology of the Scottish Intercollegiate Guidelines Network (SIGN).

23  
24 Literature was searched and graded 1-4 according to the evidence, and recommendations were  
25  
26  
27 created and graded into four classes (A/B/O/GPP).

28  
29  
30 All recommendations were agreed in a multistage consensus process, which resulted in a  
31  
32  
33 percentage of agreement (%). In brackets, the original recommendation/statement numbers (R1,  
34  
35  
36 R2, S1, S2...) and the grading is indicated. The guideline process was funded exclusively by the  
37  
38  
39 ESPEN society. The guideline shortage and dissemination was funded in part by the United  
40  
41  
42 European Gastroenterology (UEG) society, and also by the ESPEN society. For further details on  
43  
44  
45 methodology, see the full version of the ESPEN guideline [17] and the ESPEN SOP [18].  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

## 1. Indications for HPN

### 1.1 Indications

**1) HPN should be administered to those patients unable to meet their nutritional requirements via the oral and/or enteral route and who can be safely managed outside of the hospital.**

**(R1, grade GPP, strong consensus 95.8%)**

#### Commentary

PN is a life-saving therapy to those unable to meet their nutritional requirements by oral/enteral intake. No randomized controlled trial (RCT) can be conducted to compare HPN with placebo to confirm the life-saving efficacy of HPN therapy in this condition [3]. No absolute contraindications exist to the use of PN. The presence of organ failures and metabolic diseases, such as heart failure, renal failure, type 1 diabetes, may be associated with reduced tolerance to PN and may require careful and specific adaptations of the HPN program to meet the patient's specific clinical needs.

### 1.2 Criteria for effectiveness

**2) HPN should be prescribed as the primary and life-saving therapy for patients with transient-reversible or permanent-irreversible CIF due to non-malignant disease.**

**(R2, grade B, strong consensus 94.7%)**

#### Commentary

CIF is the chronic "reduction of gut function below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation is required to maintain health and/or growth", in metabolically stable patients [2]. CIF can be due to either benign or malignant disease and may be reversible or irreversible [2].

1 Crohn's disease, mesenteric ischemia, surgical complications, chronic intestinal pseudo-obstruction  
2 and radiation enteritis are the main underlying diseases which can get complicate with CIF, whereas  
3  
4 short bowel syndrome is the main pathophysiologic mechanism (around two-thirds of cases), the  
5  
6 remaining cases due to intestinal dysmotility, enterocutaneous fistulas, intestinal mechanical  
7  
8 obstruction and extensive mucosal diseases [19,20].  
9  
10  
11  
12  
13  
14  
15

16 **3) HPN can be considered for patients with CIF due to malignant disease.**

17  
18 **(R3, grade 0, strong consensus 95.8%)**

19  
20  
21  
22 **Commentary**

23  
24  
25 A recent Cochrane review [21] concluded that they were very uncertain whether total HPN improves  
26  
27 length of life in people with malignant bowel obstruction. However, the authors applied strict  
28  
29 Cochrane methodology that may be appropriate for evaluating medication efficacy, but may be less  
30  
31 applicable to assessing the role of essential nutrition [22].  
32  
33  
34  
35

36 Six prospective studies [23-28] on HPN-dependent patients for  $\geq 1$  month showed a benefit on  
37  
38 health related quality of life (QoL) measured by validated tools (EORTC QLQ-C30 or FACT-G, or TIQ).

39  
40 Three RCT evaluating the impact of HPN in patient outcome reported an improvement in energy  
41  
42 balance and, as-treated analysis, prolonged survival, increased body fat and fat free mass and  
43  
44 maximum exercise capacity and improved QoL, one of the most important outcome indicators of  
45  
46 HPN in cancer patients [29-32].  
47  
48  
49  
50

51  
52 Contraindications for HPN support in cancer patients include [33]:

53  
54  
55 a) patients not adequately informed about the aims of HPN, of its limited benefits and potential  
56  
57 complications  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

b) patients not informed of their predicted prognosis, or of the possibility of changing/withdrawing the treatment when it becomes futile

c) patients not sufficiently metabolically stable to be discharged home on PN

**4) HPN should be prescribed to prevent an earlier death from malnutrition in advanced cancer patients with CIF, if their life expectancy related to the cancer is expected to be longer than one to three months, even in those not undergoing active oncological treatment.**

**(R4, grade B, consensus 90%)**

#### **Commentary**

International guidelines [14, 33-35] generally advocate the use of PN in patients with malignancy who have failed oral and enteral nutrition (EN) and who have an expected survival longer than one to three months, which is the longest predictable survival in an individual unable to maintain adequate oral nutrition without artificial nutritional support.

A meta-analysis [36] reported that 45% of incurable cancer patients receiving HPN for malignant intestinal obstruction can survive more than three months [36]. These data are in keeping with those of a large prospective multinational case series [37].

The clinical challenge is to accurately identify those patients who are likely to survive long enough to benefit from HPN treatment. A nomogram has been developed from variables recognized as independent prognostic factors (Glasgow prognostic score, presence and site of metastases and Karnofsky performance status), aimed at estimating the 3-, 6-months and overall survival of incurable aphagic cachectic cancer patients considered for HPN [38].

1  
2  
3  
4  
5 **5) HPN can be considered for patients without intestinal failure who are not able or do not want**  
6  
7  
8 **to meet their nutritional requirements via the oral/enteral route. The patient should be clearly**  
9  
10 **informed about HPN benefits and risks.**

11 **(R5, grade GPP, consensus 89.5%)**

### 12 **Commentary**

13  
14 HPN surveys and registries report a percentage of cases who were not categorized as having either  
15  
16 benign or malignant intestinal failure [39-44]. These may include patients needing artificial  
17  
18 nutritional support who refused - or were not able to cope with - otherwise effective and clinically-  
19  
20 recommended EN [45]. Such patients may have cancer and an indwelling CVAD for chemotherapy;  
21  
22 alternatively, they may have dysphagia and elect not to have EN [46-48]. Since it is difficult to deny  
23  
24 nutritional support in clinical practice, HPN can sometimes be prescribed in these settings. Patients  
25  
26 without CIF who are not able or do not want to meet their nutritional requirements via the  
27  
28 oral/enteral route should be fully informed about the risks of PN therapy, which will likely be higher  
29  
30 (including life-threatening risks related to HPN) than EN in this setting [3, 4, 45].  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 *1.3 Criteria for safety*

42  
43  
44 **6) For a safe HPN program, the patient and/or the patient's legal representative have to give**  
45  
46 **fully informed consent to the treatment proposed.**

47  
48  
49 **(S1, strong consensus 95.7%)**

### 50 51 **Commentary**

52  
53  
54  
55 HPN is a complex, life-saving therapy that may result in serious harm if not properly prescribed,  
56  
57 prepared and administered. The aims of an HPN program include provision of evidence-based  
58  
59

1 therapy, prevention of HPN-related complications, as well as ensuring QoL is maximized [3, 4]. The  
2 HPN program shall provide an individualized, safe, effective and appropriate nutrition support plan  
3  
4 which should be supervised and evaluated on a regular basis [49, 50].  
5  
6  
7  
8  
9

10 **7) For a safe HPN program, the patient has to be sufficiently metabolically stable outside the**  
11  
12 **acute hospital setting.**  
13

14 **(S2, strong consensus 91.3%)**  
15

16 **Commentary**  
17  
18

19 The 'adequate' metabolic and clinical stability of a patient can be assessed by vital parameters,  
20 energy, protein, fluid and electrolyte balances and glycemic control; the term adequate means no  
21 immediate risk of acute imbalance after hospital discharge.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 **8) For a safe HPN program, the patient's home environment has to be adequate to safely deliver**  
35  
36 **the therapy proposed.**  
37

38 **(S3, strong consensus 95.7%)**  
39

40 **Commentary**  
41  
42

43 The home care environment should be assessed before the education program starts.  
44  
45  
46  
47  
48  
49  
50  
51

52 **9) For a safe HPN program, the patient and/or the caregiver has to be able to understand and**  
53  
54 **perform the required procedures for the safe administration of therapy.**  
55

56 **(S4, strong consensus 95.7%)**  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Commentary**

If the patient can achieve a stable HPN regimen and his/her overall clinical condition is acceptable, an education program for patients and/or caregivers should be initiated to teach correct and proper HPN care.

**10) The patient and/or the caregiver should be trained by a nutrition support team (NST) to safely infuse the PN with appropriate monitoring and prompt recognition of any complications.**

**(R6, grade GPP, strong consensus 100%)**

**Commentary**

Prescription, implementation and monitoring of an individualized HPN program shall be managed by a NST in centers with HPN management expertise [3, 10, 51-62]. Patients managed by such a dedicated patient-centered NST have better outcomes and possible lower overall costs of care [52, 63]. Besides involvement of the key-members of a NST (physician, dietician, nurse, pharmacist), specific patients will require input from physiotherapy, psychology and occupational therapy colleagues [3, 55-58].

**11) The prescribed nutritional admixture and ancillaries required for safe and effective therapy should be delivered by an experienced/certified health care provider.**

**(R7, grade GPP, strong consensus 95.7%)**

**Commentary**

The overall care plan includes a variety of pre-discharge and post-hospital care assessments that require coordination between several health-professionals and care providers within and outside

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

the hospital (Table 1). An experienced and certified health care provider is also required for the appropriate delivery of nutritional admixture and ancillaries to patient's home.

**12) The NST should provide appropriate monitoring and treatment for routine and/or emergency care, with appropriate contact details provided to the patient 24 hours per day, seven days per week.**

**(R8, grade GPP, strong consensus 100%)**

### **Commentary**

Communication with the caregivers at home (especially the home care nurse) and in the hospital seems to be a key-factor for patients [49, 58]. See Table 1.

**Table 1. Items to be included in the assessment at patient discharged on HPN [50, 62]**

- 
- Medical, physical, psychological and emotional suitability/stability of the patient
  - Stability of the PN regimen (dosage and admixture)
  - Level of home care and support required
  - Lifestyle/activities of daily living
  - Rehabilitative potential
  - Potential for QoL improvement
  - Potential for learning self-management of HPN (patient/caregivers)
  - Knowledge and experience of the home nursing team (if no self-management)
  - Basic home safety, facilities and general cleanliness instruction
  - Need for extra equipment (e.g. backpack, infusion pump, hospital bed, extra drip stand)
  - Home care provider of nutritional admixture, equipment and ancillaries
  - Reimbursement for bags, services and supplies
  - Around the clock (on-call) availability of an experienced home care provider
  - Post-discharge monitoring necessities/possibilities (including scheduled laboratory tests)
  - Medication prescription with administration details
-

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 2. CVAD and infusion pump

### 2.1 CVAD Choice

**13) The choice of CVAD and the location of the exit site shall be made by an experienced HPN NST, as well as by the patient.**

**(R9, grade GPP, strong consensus 100%)**

#### Commentary

The process of choosing a CVAD for HPN must involve the patient and the NST, including the specific professional (e.g. anesthetist, radiologist or surgeon) responsible for placing the CVAD [63,64].

**14) The exit site of the CVAD should be easily visualized and accessible for self-caring patients.**

**(R10, grade GPP, strong consensus 100%)**

#### Commentary

The patient should be involved in choosing the location of the cutaneous exit site which should, or course, also facilitate optimal self-care [65]. Proximity to wounds, prior exit sites, tracheotomies, stomas or fistulae should be avoided.

#### 2.1.1 Long-term HPN (>6 months)

**15) Tunneled CVAD or totally implanted CVADs shall be used for long-term HPN.**

**(R11, grade GPP, strong consensus 90.9%)**

#### Commentary

1 Tunneled CVAD (such as Hickman, Broviac or Groshong) or totally implantable devices (port) are  
2 usually chosen for long-term HPN (>6 months) [3]. A single lumen CVAD is preferred, as infections  
3 have been reported to occur more frequently with multiple lumen CVAD [61, 66, 67 68].  
4  
5  
6  
7  
8  
9

10 **16) Access to the upper vena cava should be the first choice for CVAD placement, via the**  
11 **internal jugular vein or subclavian vein.**  
12  
13

14 **(R12, grade B, strong consensus 100%)**  
15

16 **Commentary**  
17  
18

19 The literature search did not add any new information relating to this question when compared to  
20 the previous ESPEN guideline for CIF in adults [4].  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 **17) Right-sided access should be preferred to the left-sided approach to reduce the risk of**  
32 **thrombosis.**  
33  
34

35 **(R13, grade B, strong consensus 95.2%)**  
36  
37

38 **Commentary**  
39  
40

41 The risk of venous thrombosis is reduced with right vs. left-sided CVAD insertion [68].  
42  
43  
44  
45  
46  
47  
48

49 *2.1.2 Short-term HPN (< 6 months)*  
50  
51

52 **18) Peripherally inserted central venous catheters (PICCs) can be used if the duration of HPN is**  
53 **estimated to be less than six months.**  
54  
55

56 **(R15, grade B, strong consensus 100%)**  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Commentary

1  
2  
3 ESPEN and ASPEN guidelines [3, 69] for CIF do not recommend PICCs for long-term HPN. However,  
4  
5 many series have reported successful use of PICCS for up to four years [40, 43, 69-78]. The results  
6  
7 indicate that:  
8  
9

- 10  
11 a) PICCs seem to be associated with a lower risk of catheter-related bloodstream infection  
12  
13 (CRBSI) and a possible higher risk of catheter-related venous thrombosis  
14  
15  
16 b) the time to the occurrence of the first catheter-related complication seems to be shorter  
17  
18 with PICCs  
19  
20  
21 c) better description of the reasons for placement and outcomes of long-term PICC use in  
22  
23 routine clinical practice is required  
24  
25  
26  
27  
28  
29

30 **19) The tip of the CVAD should be placed at the level of the right atrial-superior vena cava**  
31  
32 **junction.**

33  
34  
35 **(R14, grade B, strong consensus 100%)**  
36  
37

## Commentary

38  
39  
40 Regardless of the type of catheter used and the insertion side, the location of the CVAD tip at the  
41  
42 superior vena cava-right atrium junction reduces the risk of venous thrombosis [69, 79,80].  
43  
44  
45  
46  
47  
48

### 2.2 Infusion control devices

#### 2.2.1 Overnight only

49  
50  
51  
52  
53  
54  
55 **20) HPN should be administered using an infusion pump for safety and efficacy reasons.**

56  
57  
58 **(R16, grade GPP, strong consensus 91.3%)**  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Commentary

An infusion pump is a medical device that delivers fluids, such as nutrients and medications, into a patient's body in controlled amounts [81, 82]. The use of an electronic (ambulatory) infusion pump with compatible delivery sets is considered as good practice [6, 83]. It is strongly recommended to use this device to manage and monitor the delivery of HPN [3, 4, 6, 12, 51, 84, 85].

### 2.2.2 Overnight and overday or overday only

**21) A portable pump can improve the patient's QoL when compared to stationary pumps.**

**(R18, grade GPP, strong consensus 95.7% agreement)**

## Commentary

Portable infusion pumps enabled HPN patients to gain independence [86, 87]. Benefits included maintaining desired flow, low noise, long battery life as well as increased probability of social and working rehabilitation and of good QoL.

**22) In exceptional circumstances a flow regulator can be temporarily used for HPN;**

**administration sets with only a roller clamp should not be used.**

**(R17, grade GPP, strong consensus 100%)**

## Commentary

Because of the (large) fluid volume, the hypertonicity of the PN admixture and the amount of glucose and potassium delivered, rapid administration or 'free flow' can potentially cause serious harm [84].

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### 3. Infusion line and catheter site care

#### 3.1 CVAD exit site

**23) Either a sterile gauze or sterile, transparent, semipermeable dressing should be used to cover the CVAD exit site.**

**(R19, grade B, strong consensus 90.9%)**

#### **Commentary**

Different kinds of dressings can be used for protecting the CVAD site from microbial colonization and infection, including (semi-permeable) transparent polyurethane dressings and gauze and tape.

Transparent dressings permit continuous visual inspection of the CVAD site and require less frequent changes. If there is visible pus exuding from the exit or the site is bleeding, it is better to use a gauze dressing (may be replaced every two days or sooner) until the problem is resolved [61].

A systematic review including studies on hospitalized patients reported no clear difference between gauze and tape and polyurethane dressings on the incidence of CRBSI, but I included studies were of low-quality evidence [88]. A systematic review came to the same conclusion but the quality of the included studies was also low [89]. Another systematic review, showed that the use of transparent dressings was significantly associated with an elevated relative risk of catheter tip infection (RR = 1.78; 95% CI, 1.38 to 2.30) compared with gauze dressings [90].

**24) When transparent dressings are used on tunneled or implanted CVAD exit sites, they can be replaced no more than once per week (unless the dressing is soiled or loose).**

**(R20, grade 0, strong consensus 95.5% agreement)**

#### **Commentary**

1 The frequency of dressing change remains a question of debate. A multicenter study, on bone  
2 marrow transplant patients with a tunneled randomly allocated to CVAD polyurethane dressing  
3 changes at different time intervals showed no difference in the rate of local infection but more skin  
4 toxicity was reported in the group with shorter interval dressing changes [91]. A systematic review  
5 concluded that there is currently inconclusive evidence as to whether longer intervals between  
6 CVAD dressing changes are associated with more or less CVAD-related infections [92].  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 **25) A tunneled and cuffed CVAD with a well healed exit site might not require dressing to**  
20 **prevent dislodgement.**  
21

22 **(R21, grade GPP, strong consensus 100%)**  
23

#### 24 **Commentary**

25  
26  
27

28 After the healing period ( $\pm 3$  weeks), it remains unclear if a dressing is necessary [61]. The recent  
29 ESPGHAN/ESPEN/ESPR/CSPEN guideline for pediatric parenteral nutrition access states that a  
30 tunneled CVAD with a well-healed exit site does not require dressing to prevent dislodgement (GPP);  
31 however, in children it is useful to have CVADs looped and covered [93].  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 **26) Tubing to administer HPN should be replaced within 24 hours of initiating the infusion.**  
45

46 **(R22, grade B, strong consensus 100%)**  
47  
48

#### 49 **Commentary**

50  
51  
52

53 PN is considered as a medium where several factors may influence microbial growth leading to  
54 CRBSI risk [94]. Currently there is no evidence that it is safe to extend the period of administration  
55 sets that contain lipids beyond an interval of 24 hours and this is generally accepted as best practice  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 [95-98]. The Center for Disease Control and Prevention (CDC) consider PN as an independent risk  
2 factor for CRBSI and recommend infusion set replacement after 24 hours [61]. Given that HPN  
3 patients are very often on cyclic PN, infusion sets normally will be replaced every 24 hours.  
4  
5  
6  
7  
8  
9

### 10 *3.2 Antisepsis technique*

11  
12 **27) Strict aseptic technique for the care of home CVAD shall be maintained.**

13  
14  
15 **(R23, grade A, strong consensus 100%)**

#### 16 **Commentary**

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Even though a recent systematic review revealed that there is not enough evidence to confirm whether patients receiving PN are more at risk of developing CRBSI than those who did not receive PN therapy [99], CRBSI is a common complication in patients receiving HPN [100-102].

A systematic review in adult patients receiving HPN showed an overall CRBSI rate ranged between 0.38 and 4.58 episodes/1000 catheter days (median 1.31). Gram-positive bacteria of human skin flora caused more than half of infections [103].

**28) Hand antisepsis and aseptic non-touch technique should be used when changing the dressing on CVADs.**

**(R24, grade GPP, strong consensus 100%)**

#### **Commentary**

Hand antisepsis is the most important measure to prevent contamination. Using gloves does not obviate the need for hand antisepsis. Gloves can be used when contact with blood, body fluids, secretions and excretions can be anticipated. The CDC leaves the choice of using gloves to local or

1 federal regulations, rules, or standards [61]. There is only indirect evidence demonstrating the use  
2 of non-sterile gloves is not inferior to sterile ones even in more invasive procedures such as minor  
3 skin excisions and outpatient cutaneous surgical procedures, [104, 105].  
4  
5  
6  
7  
8  
9

10 **29) A 0.5 - 2% alcoholic chlorhexidine solution shall be used during dressing changes and skin**  
11 **antiseptis; if there is a contraindication to chlorhexidine, tincture of iodine, an iodophor, or 70%**  
12 **alcohol shall be used as an alternative.**  
13  
14  
15  
16  
17

18 **(R25, grade A, strong consensus 95.2%)**  
19  
20  
21

#### 22 **Commentary**

23  
24

25 The incidence of CRBSI is significantly reduced in patients with CVAD who receive chlorhexidine  
26 gluconate versus povidone-iodine for insertion-site skin disinfection [61, 106-110]. This is also the  
27 reason why chlorhexidine is mentioned in most checklists for CVAD insertion [111].  
28  
29  
30  
31  
32  
33  
34  
35

36 **30) Hand decontamination, either by washing hands with soap and water but preferably with**  
37 **alcohol-based hand rubs, should be performed immediately before and after accessing or**  
38 **dressing a CVAD.**  
39  
40  
41  
42  
43

44 **(R26, grade B, strong consensus 95.2%)**  
45  
46

#### 47 **Commentary**

48  
49

50 Hand decontamination is a key factor in the prevention of health-care related infections which  
51 includes CVAD-related infections [61]. Several products are available: alcohol-based  
52 decontamination, non-alcohol-based decontamination, antimicrobial/antiseptic hand-washes or  
53 agents or liquid soap and water. Before using a hand-rub solution, hands should be free from dirt  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 and organic material. The solution must come into contact with all surfaces of the hand. The hands  
2 must be rubbed together vigorously, paying particular attention to the tips of the fingers, the  
3 thumbs and the areas between the fingers, until the solution has evaporated and the hands are dry.  
4  
5 This should be done immediately before and after direct patient care or contact and after removal  
6  
7 of any gloves [112].  
8  
9

10  
11 Results from a systematic review supported the use of alcohol-based hand rubbing: it removed  
12 microorganisms effectively, required less time and irritated hands less often than did handwashing  
13 with soap or other antiseptic agents and water [113]. Furthermore, the availability of bedside  
14 alcohol-based solutions increased compliance with hand hygiene among health care workers [113].  
15  
16 Other randomized trials also favored the use of alcohol-based solutions [114, 115].  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 *3.3 Connector management*

31  
32  
33 **31) A needle-free connector should be used to access intravenous tubing.**

34  
35 **(R27, grade B, strong consensus 100%)**

#### 36 37 38 **Commentary**

39  
40  
41  
42 Needleless connectors are an easy access point for infusion connection, which prevent needlestick  
43 injuries and reduce the risk of transmission of blood-borne infections to healthcare personnel [61].  
44  
45 Compared to the use of standard caps or 3-way stopcocks, they can reduce internal microbial  
46  
47 contamination and so the incidence of CRBSI, but they have to be properly disinfected [116-118].  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**32) Needle-free systems with a split septum valve may be preferred over some mechanical valves due to increased risk of infection with mechanical valves.**

**(R28, grade 0, strong consensus 100%)**

**Commentary**

Split septum connectors should be preferentially used instead of mechanical valves [61, 119]. The risk of (tip) occlusion due to negative displacement or blood reflux is to be taken into account, depending on the type of connector used [120]. Needleless connectors have to be changed no more frequently than every 72 hours or according to manufacturers' recommendations [61].

**33) Contamination risk shall be minimized by scrubbing the hub connectors (needleless connectors) with an appropriate antiseptic (alcoholic chlorhexidine preparation or alcohol 70%) and access it only with sterile devices.**

**(R29, grade A, strong consensus 100%)**

**Commentary**

Infection guidelines strongly recommend proper disinfection of access ports [121]. A systematic review revealed that the greatest risk for contamination of the CVAD after insertion was the needleless connector, with compliance with disinfection as low as 10%, but the optimal technique or disinfection time were not identified [122]. Another systematic review recommended scrubbing with chlorhexidine-alcohol for 15 seconds [123]. If the membranous septum of a needleless luer-activated connector is heavily contaminated, conventional disinfection with 70% alcohol does not reliably prevent entry of microorganisms [124].



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**34) For passive disinfection of hub connectors (needleless devices) antiseptic barrier caps should be used.**

**(R30, grade B, strong consensus 90.9%)**

**Commentary**

Since compliance with a time-consuming manual disinfection process is low, the use of an antiseptic barrier cap (placed on a luer needleless connector), which cleans the connection surface by continuous passive disinfection, was associated with a decrease in CRBSI [123, 124].

*3.4 CVAD protection*

**35) If HPN is delivered via an intravenous port, needles to access ports should be replaced at least once per week.**

**(R31, grade GPP, strong consensus 100%)**

**Commentary**

The port is placed just underneath the skin, usually in the chest. A catheter is attached to a subcutaneous pocket (made of titanium). To gain access, a needle is inserted through the skin and the rubbery self-healing membrane of the port. The CDC guideline considers the timeframe to replace needles as an ‘unresolved’ issue [61]. Because there is no clear evidence, we suggest replacing port needles at least once-a-week with the use of PN. This also gives the opportunity for some patients to safely take a bath or shower when the needle has been removed and replaced afterwards.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**36) The CVAD or CVAD site should not be submerged unprotected in water.**

**(R32, grade B, strong consensus 95.2%)**

**Commentary**

The ESPGHAN/ESPEN/ESPR/CSPEN guideline for pediatric PN access allows swimming (GPP) when a water-resistant dressing is used to cover the whole catheter and, after swimming, the exit site should be cleaned and disinfected [93]. Using a closed-hub system and waterproof catheter hub connections significantly reduces the incidence of CRBSIs (particularly infections caused by gram-negative pathogens) [126-128].

The CDC guidelines (recommendation B) allow showering if precautions can be taken to reduce the likelihood of introducing organisms into the catheter (e.g. if the catheter and connecting device are protected with an impermeable cover during the shower) [61].

**37) Sodium chloride 0.9% instead of heparin should be used to lock long-term CVAD.**

**(R33, grade B, strong consensus 95.5%)**

**Commentary**

A retrospective study [129], a randomized prospective study [130] and two systematic reviews [131, 132] demonstrated that normal saline flushing is not inferior to heparin flushing regarding CVAD occlusion, reflux dysfunction and flow dysfunction.

ESPEN guidelines for CIF do not recommend heparin because it promotes intraluminal biofilm formation and therefore potentially increases the risk of CRBSIs [129,133]. A grade B recommendation for the use of saline instead of heparin to flush and lock the CVAD is appropriate,

1 given that this approach does not increase the risk of CVAD occlusion and has a lower risk of biofilm  
2 formation in the CVAD lumen.  
3

4  
5  
6  
7  
8 **38) As an additional strategy to prevent CRBSIs, taurolidine locking should be used because of its**  
9 **favorable safety and cost profile.**

10  
11  
12 **(R34, grade B, strong consensus 100%)**

13  
14  
15  
16 **Commentary**

17  
18 For the primary prevention of CRBSI they are recommended [4]:  
19

20  
21  
22  
23 a) education of staff and patients/caregivers; hand washing and disinfection before touching  
24 CVAD and after CVAD care; hub connector disinfection before accessing; single-lumen  
25 tunneled catheters; chlorhexidine 2% for antisepsis, IV administration sets regular change.  
26  
27  
28

29  
30  
31 b) performing site care, catheter hub cleaning and changing CVAD dressings at least once  
32 weekly; avoiding CVAD care immediately after changing or emptying ostomy appliances.  
33  
34

35  
36  
37 c) avoiding in-line filters, routine replacement of CVAD, antibiotic prophylaxis and heparin  
38 lock.  
39  
40

41  
42  
43 Two RCTs [134, 135] and one retrospective analysis [136] investigated antimicrobial CVAD locking  
44 with taurolidine in the setting of HPN support for adult benign CIF. in adult benign CIF. No CRBSIs  
45 occurred in patients who received the taurolidine 1.4%-citrate-heparin formulation in contrast to  
46 CRBSIs in 7 out of 21 controls who received heparin 100 IE/mL ( $p < 0.05$ ) [134].  
47  
48  
49

50  
51  
52 Taurolidine 2% lock was compared to saline 0.9% in patients stratified in a new catheter group and  
53 a pre-existing catheter group [135]. CRBSIs/1000 catheter days were significantly lower in either the  
54 new catheter group, (0.29 vs 1.49) and in the pre-existing catheter group (0.39 vs 1.32).  
55  
56  
57  
58  
59  
60

1 A retrospective study on 270 patients who used taurolidine during 338.521 catheter-days . CRBSIs,  
2 catheter-related venous thrombosis and occlusions occurred at rates of 0.60, 0.28, and 0.12 per  
3  
4 1000 catheter-days, respectively [136]. Taurolidine was discontinued in 24 (9%) due to mild to  
5  
6 moderate adverse events. The switch to 0.9% saline resulted in an increased CRBSI rate (ratio 4.01,  
7  
8  
9  
10 p=0.02).

### 16 3.5 PICC management

18  
19 **39) If a PICC is used for HPN, a sutureless device should be used to reduce the risk of infection.**

20  
21  
22 **(R35, grade B, strong consensus 100%)**

#### 25 **Commentary**

26  
27  
28 A prospective study and a meta-analysis found that use of sutureless devices for CVAD securement  
29  
30 decreased the risk of CRBSI and dislocation [87, 101].

31  
32  
33  
34  
35  
36  
37 **40) For the securement of medium– to long-term PICCs (> 1 month) a subcutaneously anchored**  
38  
39 **stabilization device can be used to prevent migration and save time during dressing change.**

40  
41  
42 **(R36, grade 0, strong consensus 100%)**

#### 45 **Commentary**

46  
47  
48 For the securement of PICCs, a subcutaneously anchored stabilization device seems safe and cost-  
49  
50 effective , because time sparing during dressing and preventing migration of the tip, but training on  
51  
52 correct placement and removal is critical to minimize pain [137-140].  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

3.6 CVAD lumen use

**41) In multilumen catheters, a dedicated lumen should be used for PN infusion.**

**(R37, grade GPP, strong consensus 95.5%)**

**Commentary**

A previous ESPEN guideline recommended use of a single-lumen CVAD or of a dedicated lumen on a multilumen CVAD for PN administration [9]. The CDC guidelines gave no recommendation regarding the use of a dedicated lumen for PN [61]. There is lack of evidence for the use of a dedicated lumen to reduce infections, most likely due to the poor way study results were reported with a high risk of bias [141]. Therefore, the panel of the present guideline strongly agreed to confirm the recommendation made by the earlier ESPEN guidelines [9].

**42) Routine drawing of blood samples from CVAD should be avoided if possible due to an increased risk of complications.**

**(R38, grade B, strong consensus 95.2%)**

**Commentary**

Obtaining blood from the CVC has been reported to be a risk factor for CRBSI occurrence [140, 141].

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 4. Nutritional admixtures

### 4.1. PN admixture bag choice

**43) The HPN-admixture shall meet the patient's requirement.**

**(S5, strong consensus 95.7%)**

#### Commentary

PN admixtures can be compounded in single bags, dual chamber bags or three in one/all-in-one (AIO) bags (these contain separate compartments for lipid emulsion/glucose/amino acids to be opened and mixed before infusion). Vitamins and trace elements can be added prior to infusion in the home setting, if appropriate compatibility and stability [3, 4]. German guidelines advocate the use of "all-in-one nutrient mixtures" and advise that multi-bottle systems should not be used because of increased risks and more difficult handling [11, 144].

**44) Either commercially available ready-to-use admixtures or customized and tailored to the individual patient's requirements admixtures can be used for HPN.**

**(R39, grade GPP, strong consensus 95.7%)**

#### Commentary

Published data did not support definitive recommendations on the clinical advantages or disadvantages of individually compounded ("tailored" or "customized") PN admixture in comparison with commercially available ready-to-use ("premade" or "premixed") PN admixture adapted to the patient's requirements [3, 4, 145]. The controlled clinical trials do not directly compare the use of commercial ready-to-use bags with customized PN systems for patient outcomes, efficacy or safety and focus instead on evaluations following conversion from one

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

delivery approach to another system [145]. An evaluation of clinical outcomes, safety and cost should be considered before making the final determination.

**45) Customized and tailored HPN admixtures can be prepared either by individual compounding or by ready-to-use prepared and adapted commercial multi-chamber bags, according to the manufacturer instructions and using aseptic admixture technique preferably in a laminar flow cabinet.**

**(R40, grade GPP, strong consensus 100%)**

#### **Commentary**

The literature search for this guideline provided eleven articles that were considered to have some relevance to the question of comparison of commercial ready-to-use and customized PN admixture in non-critically ill patients [146-156]. Only one of the eleven articles, a conference abstract, compared different types of PN bags in the homecare setting, with all other articles evaluating the use of PN in hospital inpatients [146]. The results suggested that customized PN may be associated with a lower microbiological risk than commercial ready-to-use bags for patients with CIF; however, differences were not-statistically significant and this paper has not been published in full [146].

Given the paucity of data in the HPN setting, further studies are clearly needed to investigate the cost implications, safety and clinical outcomes of using commercial ready-to-use PN-admixtures for patients with benign and malignant CIF.

#### *4.2 Critical steps for the preparation and delivering of PN admixtures*

##### *4.2.1 Stability*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**46) Customized AIO admixture stability should be documented for the individual admixture based on checks by appropriate lab methods.**

**(R41, grade B, strong consensus 100%)**

**Commentary**

AIO stability has to be documented for the individual admixture based on checks by appropriate lab methods. Electrolytes are prone to incompatibilities (precipitations, multi-valent cations and negative charged lipid emulsifier leading to emulsion destabilization). Their correct admixing into the appropriate macro-element component is crucial; in selected cases with a high calcium need, organic instead of inorganic components might be preferable [157]. Easy to use and validated methods may be used to check for stability like for the Oil/Water stability of AIO admixtures [158, 159]

**47) Customized AIO admixture stability shall not be extrapolated from the literature.**

**(R42, grade GPP, strong consensus 95.2%)**

**Commentary**

Literature extrapolation for stability is not adequate due to the complexities of the admixtures [11, 157, 158].

**48) AIO admixture shall be completed immediately before infusion by adding trace elements and vitamins according to stability and compatibility data.**

**(R43, grade GPP, strong consensus 91.3%)**

**Commentary**



1 AIO admixture shall be completed by adding trace elements and vitamins in aseptic conditions  
2 according to stability and compatibility data. For structural/and or organizational reasons, the  
3  
4 addition may also be performed immediately before infusion through appropriately trained persons  
5  
6  
7 [11, 160, 161].  
8  
9

10  
11  
12  
13 **49) Drug admixing into AIO admixture shall be avoided, unless specific pharmaceutical data are**  
14  
15 **available to document compatibilities and stability of the AIO.**

16  
17  
18 **(R44, grade GPP, strong consensus 100%)**  
19  
20

21  
22 **Commentary**  
23

24  
25 AIO admixtures show a high potential of drug interactions leading to incompatibilities or stability  
26  
27 issues. They are normally not suited for drug admixing and, when necessary, the specific  
28  
29 pharmaceutical data have to be provided and documented as this final product represents an  
30  
31 individual drug product; the product performance and reliability after interaction with drugs is not  
32  
33 covered by the manufacturer [159, 162].  
34  
35  
36  
37  
38  
39  
40

41  
42 *4.2.2 Labelling*  
43

44  
45 **50) AIO admixtures shall be labelled for the individual patient indicating the composition (dose)**  
46  
47 **of the individual components according to standards, the date, the patient's name and**  
48  
49 **indication for handling such as storage, admixes to be made, infusion rate.**

50  
51  
52 **(R45, grade GPP, strong consensus 100%)**  
53  
54

55  
56 **Commentary**  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 AIO admixtures have to be labelled for the individual patient. Labels shall indicate the patient's  
2 name, the composition (dose) of the individual components according to standards, the date of  
3 manufacturing and expiring, instructions for handling like storage, admixes to be made, infusion  
4 rate, as well as avoidance of medication errors [ 160, 162, 163]. Specific pharmaceutical support  
5 within the NST is required and efficacious [164].  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15

#### 16 *4.2.3 Delivering*

17  
18  
19 **51) For customized AIO admixtures, the cold chain should be guaranteed during transport and at**  
20 **the patient's home.**  
21

22  
23  
24 **(R46, grade B, strong consensus 100%)**

#### 25 **Commentary**

26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Pharmaceutical safeguards must be applied for PN delivery, storage and administration at home throughout the patient's therapy. For customized AIO PN admixtures, the cold chain has to be guaranteed [157].

#### 66 *4.3. HPN admixture time and rate of infusion*

67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

**52) The hanging time for an HPN-admixture should be no longer than 24 hours.**

1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200

**(R47, grade GPP, strong consensus 100%)**

#### 1201 **Commentary**

1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300

The generally accepted maximum hanging time for a ready-to-use admixture are 24 hours. The giving set has to be changed upon each new PN dosing [11, 157, 161, 162].

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**53) At the end of cyclic PN administration, the infusion rate can be reduced to avoid rebound hypoglycemia (e.g. half of the infusion rate over the last half an hour).**

**(R48, grade GPP, strong consensus 93.8%)**

**Commentary**

At the end of a (cyclic) PN-infusion, the infusion rate has to be reduced to temper insulin need and to avoid rebound hypoglycemia. Glucose administration determines the maximum rate of PN infusion rate: (max. 5-7 mg glucose/kg/min; corresponding to about a maximum of 200 g glucose over twelve hours in 70 kg adult [157, 162] or 3-6 g glucose/kg per day [3]).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 5. Program monitoring

### 5.1 Patient monitoring

#### 5.1.1 Timing

**54) Patients receiving HPN shall be monitored at regular intervals, to review the indications, the efficacy and the risks of the treatment.**

**(R49, grade GPP, strong consensus 100%)**

#### **Commentary**

The purpose of monitoring is to “secure and improve QoL” of persons on HPN by assessing the nutritional efficacy of the HPN program, preventing and timely diagnosing and treating HPN-related complications and measuring QoL and quality of care [3, 4].

After hospital discharge, the HPN NST has contact with patients and caregivers on a regular basis, initially every few days, then weekly and eventually monthly as the patient gains confidence. The clinician who is in contact should be prepared to clarify confusing issues and also to follow weight, urine output, diarrhea or stoma output, body temperatures (before and within an hour of starting the HPN infusion when required by clinical feature), and general health.

Incidence of CRBSI, incidence of rehospitalization and QoL have been identified as the three major indicators of quality of care HPN patients with either a benign [59] or malignant [51] underlying disease. Survival rate was also considered important when patients with benign disease were considered [165].

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**55) The time between reviews should be adapted to the patient, care setting and duration of nutrition support; intervals can increase as the patient is stabilized on nutrition support.**

**(R50, grade GPP, strong consensus 100%)**

**Commentary**

Evidence-based guidelines for monitoring are not available due to the lack of published data [3-12, 166, 167]. Only one study has been published reporting monitoring practices for HPN across Europe [15]. The results showed that the majority of centers performed a 3-month monitoring interval for stable patients and emphasized that responsibility for monitoring should be assigned to a designated person on the hospital HPN specialist NST [15].

*5.1.2 Modalities*

**56) HPN monitoring should be carried out by the hospital NST in collaboration with experienced home care specialists, home care agencies and/or general practitioners.**

**(R51, grade GPP, strong consensus 100%)**

**Commentary**

Monitoring of HPN patients should also involve the general practitioner. Healthcare professionals should review the indications, route, risks, benefits and goals of nutrition support at regular intervals.

**57) Patients and/or caregivers can be trained to monitor nutritional status, fluid balance and the infusion catheter.**

**(R52, grade 0, strong consensus 95.7%)**

**Commentary**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

In long-term HPN, patients and caregivers should be trained in self-monitoring of their nutritional status, fluid balance and infusion catheter, as well as in recognizing early signs and symptoms of complications and responding to adverse changes in both their well-being and management of their nutritional delivery system.

### 5.1.3 Parameters to be monitored and frequency of monitoring

**58) Monitoring should comprise of nutritional efficacy, tolerance of PN, patient/caregiver management of infusion catheter, QoL and quality of care (e.g. CRBSI rate, readmission rate etc.).**

**(R53, grade GPP, strong consensus 95.7%)**

#### **Commentary**

Parameters to be monitored, frequency and setting of monitoring are indicated in Table 2.

**59) In clinically stable patients on long-term HPN, body weight, body composition and hydration status, energy and fluid balance and biochemistry (hemoglobin, ferritin, albumin, C-reactive protein, electrolytes, venous blood gas analysis, kidney function, liver function and glucose) should be measured at all the scheduled (e.g. every three to six months).**

**(R54, grade GPP, strong consensus 100%)**

#### **Commentary**

The time between reviews depends on the patient, care setting, duration of nutrition support as well as the expected speed with which the impairment of a parameter is likely to occur. Monitoring should be more frequent during the early months of HPN, or if there is a change in the patient's

1 clinical condition. Intervals may increase as the patient is stabilized on nutrition support. Fluid  
2 balance requires the most frequent monitoring, especially in the first period after discharge and in  
3 patients with short bowel syndrome with a high output stoma or with intestinal dysmotility with  
4 recurrent episodes of vomiting. Frequent acute dehydration episodes are responsible for kidney  
5 failure and re-hospitalization [ 168,169].  
6  
7  
8  
9  
10

11  
12  
13  
14  
15  
16 **60) In patients on long-term HPN, clinical signs and symptoms as well as biochemical indexes of**  
17 **vitamin and trace metal deficiency or toxicity should be evaluated at least once per year.**

18  
19  
20  
21 **(R55, grade GPP, strong consensus 95.7%)**  
22

23  
24 **Commentary**  
25

26  
27 Vitamin and trace metal deficiency may take more time to develop and to present clinical signs and  
28 symptoms, so that a six to twelve month interval of assessment is appropriate. Monitoring of  
29 micronutrients is important especially in patients on long-term HPN and in those who are  
30 undergoing intestinal rehabilitation and weaning from HPN. In the latter case, while intestinal  
31 rehabilitation is associated with maintenance of energy, protein, fluid and electrolyte balance  
32 without PN support, this is not necessarily the case for micronutrient balance, because decreasing  
33 or totally stopping PN infusion decreases micronutrient supplementation, thus creating a risk for  
34 deficiency [4].  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 **61) In patients on long-term HPN, bone metabolism and bone mineral density should be**  
53 **evaluated annually or in accordance with accepted standards (e.g. DXA at max. every 18**  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

months).

(R56, grade GPP, strong consensus 100%)

### Commentary

See Table 2.

**Table 2. Parameters, frequency (after baseline assessment) and setting of monitoring on patients on HPN.**

Parameter	Frequency	Setting
General condition	Daily if unstable, twice weekly to once a week if stable	Nurse at home
Body temperature	Daily if unstable, twice weekly to once a week if stable	Patient and/or caregivers
Body weight	Daily if unstable, twice weekly to once a week if stable	In the hospital (outpatient visit) Nurse at home Patient and/or caregivers
Body mass index	Monthly	In the hospital (outpatient visit) Nurse at home
Fluid balance - Urine output - Stoma output - Number or consistency of stools - Presence of edema	The frequency and type of parameters will depend on etiology of CIF, and stability of patients In case of high stool output (end jejunostomy), the monitoring after the first discharge should be daily, then twice weekly to once a week when stable	Nurse at home Patient and/or caregivers only in case of training program
Catheter cutaneous exit site	Daily	Nurse at home Patient and/or caregivers only in case of training program
Full count blood C-reactive protein Serum glucose Serum and urine electrolytes and minerals (Na, Cl, K, Mg, Ca and P) Serum Urea and Creatinine Serum bicarbonates Urine analysis	The frequency and type of parameters will depend on etiology of the underlying condition requiring HPN and the stability of patients Weekly or monthly, then every three to four months when stable	At home Verify at each visit
Serum albumin and prealbumin	Monthly, then every three to four months when stable	At home Verify at each visit
Serum liver function tests including INR	Monthly, then every three to four months when stable	At home Verify at each visit
Liver ultrasound	Yearly	In hospital
Serum Folate, vitamins B12, A and E	Every six to twelve months	Dosage at home or in the hospital
Serum ferritin iron,	Every three to six months	Dosage at home or in the hospital
Serum 25-OH Vitamin D	Every six to twelve months	Dosage at home or in the hospital
Serum zinc, copper, selenium	Every six to twelve months	Dosage in the hospital
Serum Manganese	Yearly	Dosage in the hospital
Bone densitometry (DEXA)	Every twelve to eighteen months	In the hospital



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 6. Management (nutrition support team, training, emergency, travelling)

### 6.1 Local and personnel preconditions for HPN

**62) The suitability of the home care environment should be assessed and approved by the HPN nursing team before starting HPN, wherever possible.**

**(R57, grade GPP, strong consensus 91.3%)**

#### **Commentary**

The management of PN in the home care setting differs from hospitalized patients because there is a shift in primary responsibility from health care professionals to patients and caregivers. The general goals in the education process are promoting independence with the infusion, (self-) monitoring of HPN, preventing complications and improving or maintaining QoL [3, 4] (Table 3). The HPN center NST plays a key role in the individualized decision-making process and guides all the necessary measures or steps which have to be taken [3, 10, 51-62].

**63) A formal individualized HPN training program for the patient and/or caregiver and/or home care nurses shall be performed, including catheter care, pump use and preventing, recognizing and managing complications; training can be done in an in-patient setting or at the patient's home.**

**(R58, grade GPP, strong consensus 91.3%)**

#### **Commentary**

Guidelines on core components for (catheter) infection control and prevention, give strong recommendations about the provision of education and training [60, 61]. Besides preventing CRBSI and assessing QoL, the overall teaching program has many aspects to deal with and is very often

1 driven by an experienced (nutrition support) nurse who takes the lead and responsibility for this  
2 program [3, 57]. See Table 3.  
3  
4

5 **Table 3. Content of a teaching program for patients/caregivers discharged on HPN [3, 10, 50, 62]**  
6

- 
- 7  
8  
9
- 10 • Indication for HPN: short and/or long-term goals and HPN-regimen
  - 11 • Issues around informed consent
  - 12 • Role of the home care provider to provide parenteral formulations, equipment, supplies, and eventually  
13 nursing care
  - 14 • Determine learning abilities and readiness to self-management and self-monitoring  
15 ○ If applicable: make a checklist for competencies achieved
  - 16 • Reviewing evidence-based written policies and procedures complemented with oral instructions
  - 17 • Home care environment  
18 ○ General cleanliness (for example: Is there a clean area for aseptic/sterile procedures?)  
19 ○ Presence of animals  
20 ○ Basic home safety (telephone access, clean storage for supplies, dedicated refrigerator, toilet-bathroom,  
21 sanitary water supply,...)
  - 22 • Catheter care  
23 ○ Principles of infection control and prevention (including aseptic techniques)  
24 ○ Preventing, recognizing and managing catheter related complications  
25 ○ Site care
  - 26 • Storage, handling, inspection of admixtures (e.g. leaks, labels, precipitates, color), ancillaries and  
27 (medication) supplies
  - 28 • If applicable:  
29 ○ Safe addition of vitamins, trace elements or other additives  
30 ○ Safe administration of HPN  
31 ○ Connecting and disconnecting IV tubing to the vascular access device  
32 ○ Pre/post infusion flushing  
33 ○ Periodically assessment of performance/compliance with aseptic techniques
  - 34 • Pump use, programming, pump care and troubleshooting
  - 35 • Preventing, recognizing and managing non-infectious related complications or problems
  - 36 • Most common mistakes
  - 37 • Available contact resources and post discharge support from the HPN center as well as the home care  
38 provider
  - 39 • Self HPN monitoring
  - 40 • Concomitant drug therapy and administration mode (total regimen management)
- 
- 41  
42  
43  
44  
45

46 Training for HPN may be carried out in an in-patient setting or at patient's home and may take  
47 several days to weeks depending on patient skills, duration of HPN and underlying condition. [3, 4,  
48 62].  
49

50 Patient/caregiver education at home reduces hospital length of stay and may be preferable for some  
51 patients [170]. Multiple education interventions are possible including one-on-one counselling,  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 teach-back method, written handouts, computer-assisted learning and interactive presentations  
2 (videotapes, CDs/DVDs and internet education). [50, 56, 62].  
3  
4  
5  
6  
7

8 *6.2 Requirements for the hospital centers caring for HPN patients*  
9

10  
11 **64) Patients on HPN should be cared for by specialized, dedicated and a clearly identifiable**  
12 **hospital unit, normally termed “HPN center or IF center or intestinal rehabilitation center”.**  
13  
14 **(R59, grade GPP, strong consensus 100%)**  
15  
16  
17

18  
19  
20 **Commentary**  
21

22  
23 Key issues are the identification of the persons, structures and procedures responsible for the HPN  
24 care process [4, 12, 167], such as:  
25

- 26 • Professionals who coordinate and manage the different phases of HPN management
- 27
- 28 • Place of initial care (center of intestinal failure, gastroenterology, surgery, other)
- 29
- 30 • Place and methods of training programs (on hospital beds, in day hospital, at home)
- 31
- 32 • Pathways of care in case of complications (example: emergency room, direct access to
- 33 hospital beds, link with local hospitals of the patient residency)
- 34
- 35 • Place and procedures for CVAD positioning and managing of complications
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45

46 The HPN center needs to estimate the time that each professional has to dedicate to the single  
47 patient, in order to define the number of human resources required for managing their total  
48 number of HPN patients.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**65) The HPN unit should have offices for outpatient visits and dedicated beds for patients who need hospitalization.**

**(R60, grade GPP, strong consensus 91.3%)**

**Commentary**

Hospitalization is required to monitor patients and/or evaluate intestinal function in order to better adapt treatments as well as to timely and appropriately treat complications according to the NST procedures. Hospital beds under the responsibility of the NST is essential for initial care as well as for managing of complications. These beds may be within an independent structure of nutrition/intestinal failure or within a more general structure, such as department of gastroenterology, oncology, surgery or other.

*6.3 Requirements of the NST*

**66) All HPN patients should be cared for by a NST with experience in HPN management, independent from the underlying disease leading to intestinal failure.**

**(R61, grade GPP, strong consensus 100%)**

**Commentary**

Only experienced NST should provide HPN treatment [3-7, 9-12, 164, 165], because it has been shown that experience in HPN support had a positive impact on patient survival [169] and CRBSI rates, which are considered a proxy for the quality of HPN support [64,65]. Key tasks of the NST include establishing (contra)-indications for HPN support, development and implementation of individualized training and treatment programs, treatment of complications (vascular access related, metabolic derangements) and organization of home care [171].

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**67) The NST consists of experts in HPN provision. This can include a physician, specialist nurses (including in catheter, wound and stoma care), dietitians, pharmacists, social worker, psychologist, as well as an appropriate practitioner with expertise in CVC placement. Surgeons with expertise in intestinal failure should also be available for structured consultation. (R62, grade GPP, strong consensus 100%)**

**Commentary**

The appropriate composition and size of a NST that provides HPN care to some extent depends on the number of patients under the team’s care, which mostly also relates to the patient volume and scope of the hospital [172].

The team that provides HPN support should be multidisciplinary in nature and include physician specialists with a background in surgery and gastroenterology, specialized nurses, dieticians and pharmacists [54, 55]. Psychologists and social workers should also form part of the team. This latter issue was highlighted in studies showing that many HPN patients experience the lack of attention for their psychosocial problems as a shortcoming [ 173,174].

Concerning patients with active cancer, HPN support is challenging and discussion with the treating oncology specialist seems prudent before HPN initiation [14].

Caregivers closer to the home, such as the general practitioner and homecare nurses, although not direct team members, should be kept informed of patients’ clinical course after discharge from hospital [49, 50, 56, 58].

*6.4 Travelling with HPN - organization*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**68) For a patient to travel safely, he/she shall receive a sufficient supply of PN and relevant ancillaries during the journey and at the destination and the NST responsible for the patient's care shall endeavor to establish contact with a skilled NST at the patient's destination, in case medical support is required.**

**(R70, grade GPP, strong consensus 100%)**

### **Commentary**

Patients on long-term HPN need to learn how to adjust to lifestyle events such as bathing, showering, swimming, sports and travel [ 167, 175].

Travelling patient/caregivers should discuss their travel plans with their healthcare professionals/NST to ensure that they/their child are fit to travel and to ensure that PN bag and any required facilities and ancillaries for a safe HPN therapy are provided during the travel period.

The doctor should issue a letter/medical certificate for the patient/caregivers confirming that they are aware they are travelling, along with a brief overview of their condition and need for PN. Medical cover/travel insurance should be arranged prior to travelling to ensure that any medical treatment needed while travelling will be possible. Usual healthcare professionals should consider establishing local medical support or a contact for the patient should medical support be required. In case of an emergency situation, a plan of action should be prepared beforehand and all important (doctor, family) contact numbers should be easily accessible.

### *6.5. Criteria to monitor the safety of HPN program provision*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**69) Incidence of catheter-related infection, incidence of hospital readmission and QoL should be used as criteria to assess the quality of care of HPN program.**

**(R71, grade GPP, strong consensus 100%)**

### **Commentary**

Three multicenter international studies have identified and ranked the interventions determined to be essential for good quality of care (also called ‘key interventions’) [51, 59, 165].

The top three outcome indicators identified by healthcare professionals were incidence of CRBSI, incidence of rehospitalizations and QoL for CIF due to either benign [59] or malignant [51] disease.

The top three desired outcomes of patients with benign CIF were incidence of CRBSI, survival rate, and QoL on HPN [165].

The key interventions identified should be measured annually in current practice, along with questionnaires on patients’ satisfaction, to identify and address any areas for further improvement. [4].

The outcome indicators should be measured with quality indicators related to structure, process and outcome of health care, where ‘structure’ refers to general administrative standards of the organization and people providing care, ‘process’ refers to the manner in which care is actually provided and administered and ‘outcome’ refers to a set of expected or desirable results for patients [176]. Therefore, the outcome indicators reported should be monitored along with the linked process as well as structure indicators which will help to drive quality improvement.

## *6.6 Emergency management*

### *6.6.1 Mandatory organizational features*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**70) The NST for HPN/CIF shall have clear written pathways and protocols in place for the management of patients with complications relating to HPN.**

**(R63, grade GPP, strong consensus 100%)**

**Commentary**

Complications relating to CIF should be demarcated into those relating to HPN, those relating to the patient's underlying disease leading to CIF (including any underlying oncological condition) and those unrelated to CIF. The CIF team should ensure that patients and caregivers are aware of the roles and responsibilities of the health care professionals involved in each component of their condition.

Two studies have demonstrated patient-education programs aimed at minimizing hospital admissions for complications associated with CIF, concerning protocol to treat dehydration at home for HPN patients [168] and patients' abilities to resolve problems and adequately respond to CVC-related emergency situations [174].

**71) The NST for HPN/CIF shall provide patients and caregivers with written information relating to the recognition and subsequent management of HPN-related complications, including details (e.g. telephone number) of an appropriate NST member to contact in the case of an emergency, available 24 hours per day.**

**(R64, grade GPP, strong consensus 91.3%)**

**Commentary**

The NST should be responsible for the emergency management of any HPN-related issues 24 hours per day, seven days per week. Patients and carers must be provided with clear written information



1 relating to the recognition and management of HPN-related complications, including contact details  
2 of the NST in case of any emergency.  
3  
4  
5  
6  
7

8 **72) The NST for HPN/CIF shall disseminate clear protocols relating to the recognition,**  
9  
10 **investigation and initial management of HPN-related complications to hospital emergency**  
11 **departments, where patients are likely to present; where appropriate and available, written**  
12 **protocols can also be carried by the patient or accessed electronically via a secure web-portal.**  
13  
14  
15  
16  
17  
18

19 **(R65, grade GPP, strong consensus 100%)**  
20  
21

#### 22 **Commentary**

23  
24

25 The NST should generate written protocols for the management of HPN-related complications.  
26  
27  
28  
29  
30

#### 31 *6.6.2 Actions at time of hospital admission*

32  
33

34 **73) When patients are admitted to hospital with HPN-related complications, their care shall be**  
35 **delivered by the NST for HPN/CIF; if patients are admitted to a hospital where such expertise**  
36 **does not exist, then clinical guidance should be provided by the NST for HPN/CIF, until the time**  
37 **when the patient can be transferred to the HPN/CIF center, as required.**  
38  
39  
40  
41  
42  
43

44 **(R66, grade GPP, strong consensus 100%)**  
45  
46  
47

#### 48 **Commentary**

49  
50

51 The NST should have systems in-place such that specialist advice from the NST is available at all  
52 times.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**74) Written protocols for the management of HPN-related complications shall be developed and shared with the patient’s local hospital, if it is likely that the patient will be admitted first to that hospital rather than to the HPN/CIF center in the event of an emergency; these should include contact details for the NST for HPN/CIF to advise on treatment and/or possible transfer to the HPN/CIF center. Where appropriate and available, written protocols can also be carried by the patient or accessed electronically via a secure web-portal.**

**(R67, grade GPP, strong consensus 95.5%)**

**Commentary**

Where patients cannot attend the CIF center with emergency issues (for example, if distance and/or clinical need mandates immediate care at a local hospital), the NST should ensure that shared cared-protocols have been disseminated to local hospitals in advance.

**75) Patients shall carry details relevant to their condition, and/or have access to a secure web-portal containing relevant clinical information, when travelling away from home, in order to aid clinical teams at other hospitals should emergency treatment be required.**

**(R68, grade GPP, strong consensus 100%)**

**Commentary**

The NST should provide patients with relevant details of their clinical condition.

**76) The NST for HPN/CIF shall ensure that patients, caregivers and general practitioners are aware of the roles and responsibilities of the health care professionals involved in aspects of the patient’s condition that are unrelated to HPN, including any complications relating to the**

1 **patient's underlying disease and other non-IF related conditions.**

2 **(R69, grade GPP, strong consensus 100%)**

3  
4  
5 **Commentary**

6  
7  
8 Patients and caregivers should be aware that the NST may not be responsible for all aspects of their  
9 health, including the underlying disease leading to CIF (e.g. Crohn's disease, malignancy), As soon  
10 as a patient is established on HPN, he/she and his/her general practitioner should be made aware  
11 of the relevant roles and responsibilities of the health care professionals involved in aspects of the  
12 patient's condition that are unrelated to HPN [3,11,14].  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## **Funding statement**

The guideline process was funded exclusively by the ESPEN society. The guideline shortage and dissemination was funded in part by the United European Gastroenterology (UEG) society, and also by the ESPEN society.

## **Conflicts of interest**

The expert members of the working group were accredited by the ESPEN Guidelines Group, the ESPEN Education and Clinical Practice Committee, and the ESPEN executive. All expert members have declared their individual conflicts of interest according to the rules of the International Committee of Medical Journal Editors (ICMJE). If potential conflicts were indicated, they were reviewed by the ESPEN guideline officers and, in cases of doubts, by the ESPEN executive. None of the expert panel had to be excluded from the working group or from co-authorship because of serious conflicts. The conflict of interest forms are stored at the ESPEN guideline office and can be reviewed by ESPEN members with legitimate interest upon request to the ESPEN executive.

## **Acknowledgement**

The authors thank Anna Schweinlin for expert assistance in this guideline project.

## References

- 1  
2  
3 [1] Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. ESPEN guidelines on  
4 definitions and terminology of clinical nutrition. *Clin Nutr.* 2017;36:49-64.
- 5  
6 [2] Pironi L, Arends J, Baxter J, Bozzetti F, Pelaez RB, Cuerda C, et al. ESPEN endorsed  
7 recommendations. Definition and classification of intestinal failure in adults. *Clin Nutr.* 2015;34:171-  
8 80.
- 9  
10 [3] Staun M, Pironi L, Bozzetti F, Baxter J, Forbes A, Joly F, et al. ESPEN Guidelines on Parenteral  
11 Nutrition: Home Parenteral Nutrition (HPN) in adult patients. *Clin Nutr.* 2009;28:467-79.
- 12  
13 [4] Pironi L, Arends J, Bozzetti F, Cuerda C, Gillanders L, Jeppesen PB, et al. ESPEN guidelines on  
14 chronic intestinal failure in adults. *Clin Nutr.* 2016;35:247-307.
- 15  
16 [5] Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. *JPEN J*  
17 *Parenter Enteral Nutr.* 2002;26:1sa-138sa.
- 18  
19 [6] Gillanders L, Angstmann K, Ball P, Chapman-Kiddell C, Hardy G, Hope J, et al. AuSPEN clinical  
20 practice guideline for home parenteral nutrition patients in Australia and New Zealand. *Nutrition.*  
21 2008;24:998-1012.
- 22  
23 [7] Kovacevich DS, Frederick A, Kelly D, Nishikawa R, Young L. American Society for Parenteral and  
24 Enteral Nutrition Board of Directors, Standards for specialized nutrition support: home care patients.  
25 *Nutr Clin Pract.* 2005;20:579-90.
- 26  
27 [8] Koletzko B, Jauch KW, Verwied-Jorky S, Krohn K, Mittal R. Guidelines on Parenteral Nutrition  
28 from the German Society for Nutritional Medicine (DGEM) - Part 1. *Clin Nutr.* 2008.
- 29  
30 [9] Pittiruti M, Hamilton H, Biffi R, MacFie J, Pertkiewicz M, Espen. ESPEN Guidelines on Parenteral  
31 Nutrition: central venous catheters (access, care, diagnosis and therapy of complications). *Clin Nutr.*  
32 2009;28:365-77.
- 33  
34 [10] Dreesen M, Foulon V, Vanhaecht K, De Pourcq L, Hiele M, Willems L. Guidelines  
35 recommendations on care of adult patients receiving home parenteral nutrition: a systematic  
36 review of global practices. *Clin Nutr.* 2012;31:602-8.
- 37  
38 [11] Bischoff S, Arends J, Dörje F, Engeser P, Hanke G, Köchling K, et al. S3-Leitlinie der Deutschen  
39 Gesellschaft für Ernährungsmedizin (DGEM) in Zusammenarbeit mit der GESKES und der AKE.  
40 Aktuelle Ernährungsmedizin. 2013;38:e101-e54.
- 41  
42 [12] National Collaborating Centre for Acute Care. Nutrition support for adults: oral nutrition  
43 support, enteral tube feeding and parenteral nutrition. NICE Clinical Guidelines, No. 32, 2006  
44 (<https://www.ncbi.nlm.nih.gov/books/NBK49269/>; last call 26 Oct 2022).
- 45  
46 [13] NHS England. Intestinal Failure Service (Adult). 2019 ([https://www.england.nhs.uk/wp-](https://www.england.nhs.uk/wp-content/uploads/2019/07/170077S-Intestinal-Failure-Service-Specification.pdf)  
47 [content/uploads/2019/07/170077S-Intestinal-Failure-Service-Specification.pdf](https://www.england.nhs.uk/wp-content/uploads/2019/07/170077S-Intestinal-Failure-Service-Specification.pdf); last call 26 Oct  
48 2022).
- 49  
50 [14] Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on  
51 nutrition in cancer patients. *Clin Nutr.* 2017;36:11-48.
- 52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1 [15] Wengler A, Micklewright A, Hebuterne X, Bozzetti F, Pertkiewicz M, Moreno J, et al. Monitoring  
2 of patients on home parenteral nutrition (HPN) in Europe: a questionnaire based study on  
3 monitoring practice in 42 centres. *Clin Nutr.* 2006;25:693-700.
- 4 [16] Pironi L, Steiger E, Brandt C, Joly F, Wanten G, Chambrier C, et al. Home parenteral nutrition  
5 provision modalities for chronic intestinal failure in adult patients: An international survey. *Clin Nutr.*  
6 2020;39:585-91.
- 7 [17] Pironi L, Boeykens K, Bozzetti F, Joly F, Klek S, Lal S, et al. ESPEN guideline on home parenteral  
8 nutrition. *Clin Nutr.* 2020;39:1645-66.
- 9 [18] Bischoff SC, Singer P, Koller M, Barazzoni R, Cederholm T, van Gossum A. Standard operating  
10 procedures for ESPEN guidelines and consensus papers. *Clin Nutr.* 2015;34:1043-51.
- 11 [19] Pironi L, Konrad D, Brandt C, Joly F, Wanten G, Agostini F, et al. Clinical classification of adult  
12 patients with chronic intestinal failure due to benign disease: An international multicenter cross-  
13 sectional survey. *Clin Nutr.* 2018;37:728-38.
- 14 [20] Pironi L, Goulet O, Buchman A, Messing B, Gabe S, Candusso M, et al. Outcome on home  
15 parenteral nutrition for benign intestinal failure: a review of the literature and benchmarking with  
16 the European prospective survey of ESPEN. *Clin Nutr.* 2012;31:831-45.
- 17 [21] Sowerbutts AM, Lal S, Clamp A, Todd C, Jayson G, Teubner A, et al. Home parenteral nutrition  
18 for people with inoperable malignant bowel obstruction. *Cochrane Database Syst Rev.* 2017.
- 19 [22] Bozzetti F, Forbes A. The ESPEN clinical practice Guidelines on Parenteral Nutrition: present  
20 status and perspectives for future research. *Clin Nutr.* 2009;28:359-64.
- 21 [23] Finocchiaro C, Gervasio S, Fadda M, Amerio ML, D'Andrea F, Domeniconi D, et al. Home  
22 parenteral nutrition (HPN): Survival in advanced cancer patients. *Clin Nutr.* 2003;22:S65.
- 23 [24] Seys P, Tadmouri A, Senesse P, Radji A, Rotarski M, Balian A, et al. [Home parenteral nutrition  
24 in elderly patients with cancer: an observational prospective study]. *Bull Cancer.* 2014;101:243-9.
- 25 [25] Culine S, Chambrier C, Tadmouri A, Senesse P, Seys P, Radji A, et al. Home parenteral nutrition  
26 improves quality of life and nutritional status in patients with cancer: a French observational  
27 multicentre study. *Support Care Cancer.* 2014;22:1867-74.
- 28 [26] Vashi PG, Dahlk S, Popiel B, Lammersfeld CA, Ireton-Jones C, Gupta D. A longitudinal study  
29 investigating quality of life and nutritional outcomes in advanced cancer patients receiving home  
30 parenteral nutrition. *BMC Cancer.* 2014;14:593.
- 31 [27] Girke J, Seipt C, Markowski A, Luettig B, Schettler A, Momma M, et al. Quality of Life and  
32 Nutrition Condition of Patients Improve Under Home Parenteral Nutrition: An Exploratory Study.  
33 *Nutr Clin Pract.* 2016;31:659-65.
- 34 [28] Cotogni P, De Carli L, Passera R, Amerio ML, Agnello E, Fadda M, et al. Longitudinal study of  
35 quality of life in advanced cancer patients on home parenteral nutrition. *Cancer Med.* 2017;6:1799-  
36 806.
- 37 [29] Hyltander A, Drott C, Unsgaard B, Tolli J, Korner U, Arfvidsson B, et al. The effect on body  
38 composition and exercise performance of home parenteral nutrition when given as adjunct to  
39 chemotherapy of testicular carcinoma. *Eur J Clin Invest.* 1991;21:413-20.
- 40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1 [30] Lundholm K, Daneryd P, Bosaeus I, Korner U, Lindholm E. Palliative nutritional intervention in  
2 addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease:  
3 Effects on survival, metabolism, and function. *Cancer*. 2004;100:1967-77.
- 4 [31] Lundholm K, Korner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, et al. Insulin  
5 treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. *Clin Cancer*  
6 *Res*. 2007;13:2699-706.
- 7 [32] Obling SR, Wilson BV, Pfeiffer P, Kjeldsen J. Home parenteral nutrition increases fat free mass  
8 in patients with incurable gastrointestinal cancer. Results of a randomized controlled trial. *Clin Nutr*.  
9 2019;38:182-90.
- 10 [33] Bozzetti F, Amadori D, Bruera E, Cozzaglio L, Corli O, Filiberti A, et al. Guidelines on artificial  
11 nutrition versus hydration in terminal cancer patients. *European Association for Palliative Care*.  
12 *Nutrition*. 1996;12:163-7.
- 13 [34] Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, Muscaritoli M, et al. ESPEN  
14 Guidelines on Parenteral Nutrition: non-surgical oncology. *Clin Nutr*. 2009;28:445-54.
- 15 [35] August DA, Huhmann MB, American Society for P, Enteral Nutrition Board of D. A.S.P.E.N.  
16 clinical guidelines: nutrition support therapy during adult anticancer treatment and in  
17 hematopoietic cell transplantation. *JPEN J Parenter Enteral Nutr*. 2009;33:472-500.
- 18 [36] Naghibi M, Smith TR, Elia M. A systematic review with meta-analysis of survival, quality of life  
19 and cost-effectiveness of home parenteral nutrition in patients with inoperable malignant bowel  
20 obstruction. *Clin Nutr*. 2015;34:825-37.
- 21 [37] Bozzetti F, Santarpia L, Pironi L, Thul P, Klek S, Gavazzi C, et al. The prognosis of incurable  
22 cachectic cancer patients on home parenteral nutrition: a multi-centre observational study with  
23 prospective follow-up of 414 patients. *Ann Oncol*. 2014;25:487-93.
- 24 [38] Bozzetti F, Cotogni P, Lo Vullo S, Pironi L, Giardiello D, Mariani L. Development and validation  
25 of a nomogram to predict survival in incurable cachectic cancer patients on home parenteral  
26 nutrition. *Ann Oncol*. 2015;26:2335-40.
- 27 [39] Wanden-Berghe C, Luengo LM, Alvarez J, Burgos R, Cuerda C, Matia P, et al. Spanish home  
28 enteral nutrition registry of the year 2014 and 2015 from the NADYA-SENPE Group. *Nutr Hosp*.  
29 2017;34:15-8.
- 30 [40] Winkler MF, DiMaria-Ghalili RA, Guenter P, Resnick HE, Robinson L, Lyman B, et al.  
31 Characteristics of a Cohort of Home Parenteral Nutrition Patients at the Time of Enrollment in the  
32 Sustain Registry. *JPEN J Parenter Enteral Nutr*. 2016;40:1140-9.
- 33 [41] Smith T, Naghibi M, Stratton R, White S, Hughes SJ, Small M, et al. Artificial nutrition support in  
34 the UK 2005 - 2015. Adult home parenteral nutrition & home intravenous fluids A report by the  
35 British artificial nutrition survey (BANS), a committee of BAPEN (the British association for  
36 parenteral and enteral nutrition)2016.
- 37 [42] Pironi L, Candusso M, Biondo A, Bosco A, Castaldi P, Contaldo F, et al. Prevalence of home  
38 artificial nutrition in Italy in 2005: a survey by the Italian Society for Parenteral and Enteral Nutrition  
39 (SINPE). *Clin Nutr*. 2007;26:123-32.
- 40 [43] Hortencio TDR, Arendt BM, Teterina A, Jeejeebhoy KN, Gramlich LM, Whittaker JS, et al.  
41 Changes in Home Parenteral Nutrition Practice Based on the Canadian Home Parenteral Nutrition  
42 Patient Registry. *JPEN J Parenter Enteral Nutr*. 2017;41:830-6.

- 1 [44] Pironi L. Development of home artificial nutrition in Italy over a seven year period: 2005–2012. BMC Nutrition. 2017;3.[45] Bischoff SC, Austin P, Boeykens K, Chourdakis M, Cuerda C, Jonkers-Schuitema C, et al. ESPEN guideline on home enteral nutrition. Clin Nutr. 2020;39:5-22.
- 2  
3  
4 [46] Burgos R, Breton I, Cereda E, Desport JC, Dziewas R, Genton L, et al. ESPEN guideline clinical  
5 nutrition in neurology. Clin Nutr. 2018;37:354-96.  
6
- 7 [47] Kirby DF, Corrigan ML, Hendrickson E, Emery DM. Overview of Home Parenteral Nutrition: An  
8 Update. Nutr Clin Pract. 2017;32:739-52.  
9
- 10 [48] Hotta M, Araki M, Urano A, Ohwada R. Home parenteral nutrition therapy in seven patients  
11 with anorexia nervosa: the role and indications. Intern Med. 2014;53:2695-9.  
12
- 13 [49] Kumpf VJ, Tillman EM. Home parenteral nutrition: safe transition from hospital to home. Nutr  
14 Clin Pract. 2012;27:749-57.  
15
- 16 [50] Durfee SM, Adams SC, Arthur E, Corrigan ML, Hammond K, Kovacevich DS, et al. A.S.P.E.N.  
17 Standards for Nutrition Support: Home and Alternate Site Care. Nutr Clin Pract. 2014;29:542-55.  
18
- 19 [51] Dreesen M, Foulon V, Hiele M, Vanhaecht K, De Pourcq L, Pironi L, et al. Quality of care for  
20 cancer patients on home parenteral nutrition: development of key interventions and outcome  
21 indicators using a two-round Delphi approach. Support Care Cancer. 2013;21:1373-81.  
22  
23
- 24 [52] Vashi PG, Virginkar N, Popiel B, Edwin P, Gupta D. Incidence of and factors associated with  
25 catheter-related bloodstream infection in patients with advanced solid tumors on home parenteral  
26 nutrition managed using a standardized catheter care protocol. BMC Infect Dis. 2017;17:372.  
27
- 28 [53] Pichitchaipitak O, Ckumdee S, Apivanich S, Chotiprasitsakul D, Shantavasinkul PC. Predictive  
29 factors of catheter-related bloodstream infection in patients receiving home parenteral nutrition.  
30 Nutrition. 2018;46:1-6.  
31  
32
- 33 [54] Winkler M, Guenter P. Long-term home parenteral nutrition: it takes an interdisciplinary  
34 approach. J Infus Nurs. 2014;37:389-95.  
35
- 36 [55] Dibb M, Teubner A, Theis V, Shaffer J, Lal S. Review article: the management of long-term  
37 parenteral nutrition. Aliment Pharmacol Ther. 2013;37:587-603.  
38
- 39 [56] Dibb M, Lal S. Home Parenteral Nutrition: Vascular Access and Related Complications. Nutr Clin  
40 Pract. 2017;32:769-76.  
41
- 42 [57] Boeykens K, Van Hecke A. Advanced practice nursing: Nutrition Nurse Specialist role and  
43 function. Clin Nutr ESPEN. 2018;26:72-6.  
44
- 45 [58] Dreesen M, Foulon V, Vanhaecht K, De Pourcq L, Hiele M, Willems L. Identifying patient-  
46 centered quality indicators for the care of adult home parenteral nutrition (HPN) patients. JPEN J  
47 Parenter Enteral Nutr. 2014;38:840-6.  
48  
49
- 50 [59] Dreesen M, Foulon V, Vanhaecht K, Hiele M, De Pourcq L, Pironi L, et al. Development of quality  
51 of care interventions for adult patients on home parenteral nutrition (HPN) with a benign underlying  
52 disease using a two-round Delphi approach. Clin Nutr. 2013;32:59-64.  
53
- 54 [60] Storr J, Twyman A, Zingg W, Damani N, Kilpatrick C, Reilly J, et al. Core components for effective  
55 infection prevention and control programmes: new WHO evidence-based recommendations.  
56 Antimicrob Resist Infect Control. 2017;6:6.  
57  
58  
59  
60  
61  
62  
63  
64  
65



- 1 [61] O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the  
2 prevention of intravascular catheter-related infections. *Clin Infect Dis*. 2011;52:e162-93.
- 3 [62] Boeykens K. Monitoring patients on home parenteral nutrition. In: Bozzetti F, Staun M, Van  
4 Gossum A, editors. *Home Parenteral Nutrition*. 2nd ed: CABInternational; 2015. p. 318-24.
- 5 [63] Schneider PJ. Nutrition support teams: an evidence-based practice. *Nutr Clin Pract*. 2006;21:62-  
6 7.
- 8 [64] Carreira Villamor JM, Reyes Pérez R, Pulido-Duque JM, Gorriz Gómez E, Pardo MD, Argiles Vives  
9 JM, et al. [Percutaneous implant of Hickman catheters and reservoirs. Long-term experience]. *Rev*  
10 *Clin Esp*. 1997;197:740-4.
- 11 [65] Steiger E. Obtaining and maintaining vascular access in the home parenteral nutrition patient.  
12 *JPEN J Parenter Enteral Nutr*. 2002;26:S17-20.
- 13 [66] Kuizon D, Gordon SM, Dolmatch BL. Single-lumen subcutaneous ports inserted by  
14 interventional radiologists in patients undergoing chemotherapy: incidence of infection and  
15 outcome of attempted catheter salvage. *Arch Intern Med*. 2001;161:406-10.
- 16 [67] Raman M, Gramlich L, Whittaker S, Allard JP. Canadian home total parenteral nutrition registry:  
17 preliminary data on the patient population. *Can J Gastroenterol*. 2007;21:643-8.
- 18 [68] Verso M, Agnelli G, Kamphuisen PW, Ageno W, Bazzan M, Lazzaro A, et al. Risk factors for upper  
19 limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. *Intern*  
20 *Emerg Med*. 2008;3:117-22.
- 21 [69] Kovacevich DS, Corrigan M, Ross VM, McKeever L, Hall AM, Braunschweig C. American Society  
22 for Parenteral and Enteral Nutrition Guidelines for the Selection and Care of Central Venous Access  
23 Devices for Adult Home Parenteral Nutrition Administration. *JPEN J Parenter Enteral Nutr*.  
24 2019;43:15-31.
- 25 [70] Santacruz E, Mateo-Lobo R, Riveiro J, Nattero L, Vega-Pinero B, Lomba G, et al. Infectious  
26 complications in home parenteral nutrition: A long-term study with peripherally inserted central  
27 catheters, tunneled catheters, and ports. *Nutrition*. 2019;58:89-93.
- 28 [71] Santacruz-Cerdan E, Arcano K, Arrieta Blanco F, Ortiz Flores A, Mateo Lobo R, Botella Carretero  
29 JI, et al. Effectiveness of long-term home parenteral nutrition with peripherally inserted central  
30 catheter: a case report. *Nutr Hosp*. 2016;33:185-7.
- 31 [72] Christensen LD, Holst M, Bech LF, Drustrup L, Nygaard L, Skallerup A, et al. Comparison of  
32 complications associated with peripherally inserted central catheters and Hickman catheters in  
33 patients with intestinal failure receiving home parenteral nutrition. Six-year follow up study. *Clin*  
34 *Nutr*. 2016;35:912-7.
- 35 [73] Cotogni P, Barbero C, Garrino C, Degiorgis C, Mussa B, De Francesco A, et al. Peripherally  
36 inserted central catheters in non-hospitalized cancer patients: 5-year results of a prospective study.  
37 *Support Care Cancer*. 2015;23:403-9.
- 38 [74] Toure A, Duchamp A, Peraldi C, Barnoud D, Lauerjat M, Gelas P, et al. A comparative study of  
39 peripherally-inserted and Broviac catheter complications in home parenteral nutrition patients. *Clin*  
40 *Nutr*. 2015;34:49-52.
- 41 [75] Bech LF, Drustrup L, Nygaard L, Skallerup A, Christensen LD, Vinter-Jensen L, et al.  
42 Environmental Risk Factors for Developing Catheter-Related Bloodstream Infection in Home  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Parenteral Nutrition Patients: A 6-Year Follow-up Study. JPEN J Parenter Enteral Nutr. 2016;40:989-  
2 94.

3 [76] Ross VM, Guenter P, Corrigan ML, Kovacevich D, Winkler MF, Resnick HE, et al. Central venous  
4 catheter infections in home parenteral nutrition patients: Outcomes from Sustain: American Society  
5 for Parenteral and Enteral Nutrition's National Patient Registry for Nutrition Care. Am J Infect  
6 Control. 2016;44:1462-8.

7  
8 [77] Opilla M. Peripherally Inserted Central Catheter Experience in Long-Term Home Parenteral  
9 Nutrition Patients. Journal of the Association for Vascular Access. 2017;22:42-5.

10  
11 [78] Hon K, Bihari S, Holt A, Bersten A, Kulkarni H. Rate of Catheter-Related Bloodstream Infections  
12 Between Tunneled Central Venous Catheters Versus Peripherally Inserted Central Catheters in Adult  
13 Home Parenteral Nutrition: A Meta-analysis. JPEN J Parenter Enteral Nutr. 2019;43:41-53.

14  
15 [79] Petersen J, Delaney JH, Brakstad MT, Rowbotham RK, Bagley CM. Silicone venous access devices  
16 positioned with their tips high in the superior vena cava are more likely to malfunction. The  
17 American Journal of Surgery. 1999;178:38-41.

18  
19 [80] Cadman A, Lawrance JA, Fitzsimmons L, Spencer-Shaw A, Swindell R. To clot or not to clot? That  
20 is the question in central venous catheters. Clin Radiol. 2004;59:349-55.

21  
22 [81] Hurt RT, Steiger E. Early History of Home Parenteral Nutrition: From Hospital to Home. Nutr Clin  
23 Pract. 2018;33:598-613.

24  
25 [82] [https://www.fda.gov/medicaldevices/productsandmedicalprocedures/  
26 generalhospitaldevicesandsupplies/infusionpumps/.](https://www.fda.gov/medicaldevices/productsandmedicalprocedures/generalhospitaldevicesandsupplies/infusionpumps/)

27  
28 [83] Ayers P, Adams S, Boullata J, Gervasio J, Holcombe B, Kraft MD, et al. A.S.P.E.N. parenteral  
29 nutrition safety consensus recommendations: translation into practice. Nutr Clin Pract.  
30 2014;29:277-82.

31  
32 [84] Mirtallo J, Canada T, Johnson D, Kumpf V, Petersen C, Sacks G, et al. Safe practices for parenteral  
33 nutrition. JPEN J Parenter Enteral Nutr. 2004;28:S39-70.

34  
35 [85] Auty B. The DHSS evaluation programme for infusion control instruments. Eng Med.  
36 1986;15:175-83.

37  
38 [86] Saqui O, Fernandes G, Allard JP. Quality of life analysis during transition from stationary to  
39 portable infusion pump in home parenteral nutrition patients: a Canadian experience. Nutr Clin  
40 Pract. 2014;29:131-41.

41  
42 [87] Boutin J, Hagan E. Patients' preference regarding portable pumps. J Intraven Nurs. 1992;15:230-  
43 2.

44  
45 [88] Ullman AJ, Cooke ML, Mitchell M, Lin F, New K, Long DA, et al. Dressing and securement for  
46 central venous access devices (CVADs): A Cochrane systematic review. Int J Nurs Stud. 2016;59:177-  
47 96.

48  
49 [89] Gillies D, O'Riordan E, Carr D, O'Brien I, Frost J, Gunning R. Central venous catheter dressings: a  
50 systematic review. J Adv Nurs. 2003;44:623-32.

51  
52 [90] Hoffmann KK. Transparent Polyurethane Film as an Intravenous Catheter Dressing. JAMA.  
53 1992;267:2072.

- 1 [91] Laura R, Degl'Innocenti M, Mocali M, Alberani F, Boschi S, Giraudi A, et al. Comparison of two  
2 different time interval protocols for central venous catheter dressing in bone marrow transplant  
3 patients: results of a randomized, multicenter study. The Italian Nurse Bone Marrow Transplant  
4 Group (GITMO). *Haematologica*. 2000;85:275-9.
- 5 [92] Gavin NC, Webster J, Chan RJ, Rickard CM, Gavin NC. Frequency of dressing changes for central  
6 venous access devices on catheter-related infections. *Cochrane Database Syst Rev*: John Wiley &  
7 Sons, Ltd; 2011.
- 8 [93] Kolacek S, Puntis JWL, Hojsak I. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric  
9 parenteral nutrition: venous access. *Clin Nutr* 2018;37:2379-91.
- 10 [94] Austin PD, Hand KS, Elia M. Systematic review and meta-analyses of the effect of lipid emulsion  
11 on microbial growth in parenteral nutrition. *J Hosp Infect*. 2016;94:307-19.
- 12 [95] Raad I, Hanna HA, Awad A, Alrahwan A, Bivins C, Khan A, et al. Optimal frequency of changing  
13 intravenous administration sets: is it safe to prolong use beyond 72 hours? *Infect Control Hosp*  
14 *Epidemiol*. 2001;22:136-9.
- 15 [96] Sitges-Serra A, Liñares J, Pérez JL, Jaurrieta E, Lorente L. A Randomized Trial on the Effect of  
16 Tubing Changes on Hub Contamination and Catheter Sepsis during Parenteral Nutrition. *Journal of*  
17 *Parenteral and Enteral Nutrition*. 1985;9:322-5.
- 18 [97] Ullman AJ, Cooke ML, Gillies D, Marsh NM, Daud A, McGrail MR, et al. Optimal timing for  
19 intravascular administration set replacement. *Cochrane Database Syst Rev*. 2013:CD003588.
- 20 [98] Gillies D, O'Riordan L, Wallen M, Rankin K, Morrison A, Nagy S. Timing of intravenous  
21 administration set changes: a systematic review. *Infect Control Hosp Epidemiol*. 2004;25:240-50.
- 22 [99] Gavin NC, Button E, Keogh S, McMillan D, Rickard C. Does Parenteral Nutrition Increase the Risk  
23 of Catheter-Related Bloodstream Infection? A Systematic Literature Review. *JPEN J Parenter Enteral*  
24 *Nutr*. 2017;41:918-28.
- 25 [100] Santarpia L, Buonomo A, Pagano MC, Alfonsi L, Foggia M, Mottola M, et al. Central venous  
26 catheter related bloodstream infections in adult patients on home parenteral nutrition: Prevalence,  
27 predictive factors, therapeutic outcome. *Clin Nutr*. 2016;35:1394-8.
- 28 [101] Edakkanambeth Varayil J, Whitaker JA, Okano A, Carnell JJ, Davidson JB,ENZLER MJ, et al.  
29 Catheter Salvage After Catheter-Related Bloodstream Infection During Home Parenteral Nutrition.  
30 *JPEN J Parenter Enteral Nutr*. 2017;41:481-8.
- 31 [102] Cotogni P, Pittiruti M, Barbero C, Monge T, Palmo A, Boggio Bertinet D. Catheter-related  
32 complications in cancer patients on home parenteral nutrition: a prospective study of over 51,000  
33 catheter days. *JPEN J Parenter Enteral Nutr*. 2013;37:375-83.
- 34 [103] Dreesen M, Foulon V, Spriet I, Goossens GA, Hiele M, De Pourcq L, et al. Epidemiology of  
35 catheter-related infections in adult patients receiving home parenteral nutrition: a systematic  
36 review. *Clin Nutr*. 2013;32:16-26.
- 37 [104] Brewer JD, Gonzalez AB, Baum CL, Arpey CJ, Roenigk RK, Otley CC, et al. Comparison of Sterile  
38 vs Nonsterile Gloves in Cutaneous Surgery and Common Outpatient Dental Procedures: A  
39 Systematic Review and Meta-analysis. *JAMA Dermatol*. 2016;152:1008-14.
- 40 [105] Heal C, Sriharan S, Buttner PG, Kimber D. Comparing non-sterile to sterile gloves for minor  
41 surgery: a prospective randomised controlled non-inferiority trial. *Med J Aust*. 2015;202:27-31.
- 42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1 [106] Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-  
2 iodine solution for vascular catheter-site care: a meta-analysis. *Ann Intern Med.* 2002;136:792-801.
- 3 [107] Mimoz O, Lucet J-C, Kerforne T, Pascal J, Souweine B, Goudet V, et al. Skin antisepsis with  
4 chlorhexidine–alcohol versus povidone iodine–alcohol, with and without skin scrubbing, for  
5 prevention of intravascular-catheter-related infection (CLEAN): an open-label, multicentre,  
6 randomised, controlled, two-by-two factorial trial. *The Lancet.* 2015;386:2069-77.
- 7 [108] Lai NM, Lai NA, O’Riordan E, Chaiyakunapruk N, Taylor JE, Tan K. Skin antisepsis for reducing  
8 central venous catheter-related infections. *Cochrane Database Syst Rev.* 2016;7:CD010140.
- 9 [109] Darouiche RO, Wall MJ, Jr., Itani KM, Otterson MF, Webb AL, Carrick MM, et al. Chlorhexidine-  
10 Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. *N Engl J Med.* 2010;362:18-26.
- 11 [110] Yasuda H, Sanui M, Komuro T, Hatakeyama J, Matsukubo S, Kawano S, et al. Comparison of  
12 three cutaneous antiseptic solutions for the prevention of catheter colonization in an ICU for adult  
13 patients: a multicenter prospective randomized controlled trial. *Critical Care.* 2015;19:P73.
- 14 [111] Blot K, Bergs J, Vogelaers D, Blot S, Vandijck D. Prevention of central line-associated  
15 bloodstream infections through quality improvement interventions: a systematic review and meta-  
16 analysis. *Clin Infect Dis.* 2014;59:96-105.
- 17 [112] National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance.  
18 Infection: Prevention and Control of Healthcare-Associated Infections in Primary and Community  
19 Care: Partial Update of NICE Clinical Guideline 2. London: Royal College of Physicians (UK)  
20 Copyright © 2012, National Clinical Guideline Centre.; 2012.
- 21 [113] Picheansathian W. A systematic review on the effectiveness of alcohol-based solutions for  
22 hand hygiene. *Int J Nurs Pract.* 2004;10:3-9.
- 23 [114] Girou E, Loyeau S, Legrand P, Oppein F, Brun-Buisson C. Efficacy of handrubbing with alcohol  
24 based solution versus standard handwashing with antiseptic soap: randomised clinical trial. *BMJ.*  
25 2002;325:362.
- 26 [115] Kac G, Podglajen I, Gueneret M, Vaupre S, Bissery A, Meyer G. Microbiological evaluation of  
27 two hand hygiene procedures achieved by healthcare workers during routine patient care: a  
28 randomized study. *J Hosp Infect.* 2005;60:32-9.
- 29 [116] Casey AL, Burnell S, Whinn H, Worthington T, Faroqui MH, Elliott TS. A prospective clinical trial  
30 to evaluate the microbial barrier of a needleless connector. *J Hosp Infect.* 2007;65:212-8.
- 31 [117] Yébenes JC, Vidaur L, Serra-Prat M, Sirvent JM, Batlle J, Motje M, et al. Prevention of catheter-  
32 related bloodstream infection in critically ill patients using a disinfectable, needle-free connector: A  
33 randomized controlled trial. *Am J Infect Control.* 2004;32:291-5.
- 34 [118] Casey AL, Worthington T, Lambert PA, Quinn D, Faroqui MH, Elliott TSJ. A randomized,  
35 prospective clinical trial to assess the potential infection risk associated with the PosiFlow®  
36 needleless connector. *J Hosp Infect.* 2003;54:288-93.
- 37 [119] Btaiche IF, Kovacevich DS, Khalidi N, Papke LF. The effects of needleless connectors on  
38 catheter-related bloodstream infections. *Am J Infect Control.* 2011;39:277-83.
- 39 [120] Williams A. Catheter Occlusion in Home Infusion: The Influence of Needleless Connector  
40 Design on Central Catheter Occlusion. *J Infus Nurs.* 2018;41:52-7.

- 1 [121] Ling ML, Apisarnthanarak A, Jaggi N, Harrington G, Morikane K, Thu le TA, et al. APSIC guide  
2 for prevention of Central Line Associated Bloodstream Infections (CLABSI). *Antimicrob Resist Infect*  
3 *Control*. 2016;5:16.
- 4 [122] Moureau NL, Flynn J. Disinfection of Needleless Connector Hubs: Clinical Evidence Systematic  
5 Review. *Nurs Res Pract*. 2015;2015:796762.
- 6 [123] Breimer L, Geijer H, Berggren L. [Disinfection of injection ports - a systematic overview of  
7 optimal scrub-time]. *Lakartidningen*. 2018;115.
- 8 [124] Menyhay SZ, Maki DG. Disinfection of needleless catheter connectors and access ports with  
9 alcohol may not prevent microbial entry: the promise of a novel antiseptic-barrier cap. *Infect Control*  
10 *Hosp Epidemiol*. 2006;27:23-7.
- 11 [125] Voor In 't Holt AF, Helder OK, Vos MC, Schafthuizen L, Sülz S, van den Hoogen A, et al.  
12 Antiseptic barrier cap effective in reducing central line associated bloodstream infections: a  
13 systematic review and meta-analysis. *Int J Nurs Stud* 2017;69:34-40.
- 14 [126] Robbins J, Cromwell P, Korones DN. Swimming and central venous catheter-related infections  
15 in the child with cancer. *J Pediatr Oncol Nurs*. 1999;16:51-6.
- 16 [127] Miller J, Dalton MK, Duggan C, Lam S, Iglesias J, Jaksic T, et al. Going with the flow or swimming  
17 against the tide: should children with central venous catheters swim? *Nutr Clin Pract*. 2014;29:97-  
18 109.
- 19 [128] Ivy DD, Calderbank M, Wagner BD, Dolan S, Nyquist AC, Wade M, et al. Closed-hub systems  
20 with protected connections and the reduction of risk of catheter-related bloodstream infection in  
21 pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension. *Infect*  
22 *Control Hosp Epidemiol*. 2009;30:823-9.
- 23 [129] Brito ARO, Nishinari K, Saad PF, Saad KR, Pereira MAT, Emidio SCD, et al. Comparison between  
24 Saline Solution Containing Heparin versus Saline Solution in the Lock of Totally Implantable  
25 Catheters. *Ann Vasc Surg*. 2018;47:85-9.
- 26 [130] Dal Molin A, Allara E, Montani D, Milani S, Frassati C, Cossu S, et al. Flushing the central venous  
27 catheter: is heparin necessary? *The journal of vascular access*. 2014;15:241-8.
- 28 [131] Dal Molin A, Clerico M, Baccini M, Guerretta L, Sartorello B, Rasero L. Normal saline versus  
29 heparin solution to lock totally implanted venous access devices: Results from a multicenter  
30 randomized trial. *Eur J Oncol Nurs*. 2015;19:638-43.
- 31 [132] Shanks RM, Donegan NP, Graber ML, Buckingham SE, Zegans ME, Cheung AL, et al. Heparin  
32 stimulates *Staphylococcus aureus* biofilm formation. *Infect Immun*. 2005;73:4596-606.
- 33 [133] Allon M. Prophylaxis against dialysis catheter-related bacteremia: a glimmer of hope. *Am J*  
34 *Kidney Dis*. 2008;51:165-8.
- 35 [134] Tribler S, Brandt CF, Petersen AH, Petersen JH, Fuglsang KA, Staun M, et al. Taurolidine-citrate-  
36 heparin lock reduces catheter-related bloodstream infections in intestinal failure patients  
37 dependent on home parenteral support: a randomized, placebo-controlled trial. *Am J Clin Nutr*.  
38 2017;106:839-48.
- 39 [135] Wouters Y, Theilla M, Singer P, Tribler S, Jeppesen PB, Pironi L, et al. Randomised clinical trial:  
40 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition. *Aliment*  
41 *Pharmacol Ther* 2018;48:410-22

- 1 [136] Wouters Y, Roosenboom B, Causevic E, Kievit W, Groenewoud H, Wanten GJA. Clinical  
2 outcomes of home parenteral nutrition patients using taurolidine as catheter lock: A long-term  
3 cohort study. *Clin Nutr*. 2019;38:2210-8.
- 4 [137] Zerla PA, Canelli A, Cerne L, Caravella G, Gilardini A, De Luca G, et al. Evaluating safety, efficacy,  
5 and cost-effectiveness of PICC securement by subcutaneously anchored stabilization device. *The*  
6 *journal of vascular access*. 2017;18:238-42.
- 7 [138] Macmillan T, Pennington M, Summers JA, Goddard K, Zala D, Herz N, et al. SecurA cath for  
8 Securing Peripherally Inserted Central Catheters: A NICE Medical Technology Guidance. *Appl Health*  
9 *Econ Health Policy*. 2018;16:779-91.
- 10 [139] Goossens GA, Grumiaux N, Janssens C, Jérôme M, Fieuws S, Moons P, et al. SecurAstaP trial:  
11 securement with SecurA cath versus StatLock for peripherally inserted central catheters, a  
12 randomised open trial. *BMJ open*. 2018;8:e016058-e.
- 13 [140] Elen Hughes M. Reducing PICC migrations and improving patient outcomes. *Br J Nurs*.  
14 2014;23:S12, S4-8.
- 15 [141] Gavin NC, Button E, Castillo MI, Ray-Barruel G, Keogh S, McMillan DJ, et al. Does a Dedicated  
16 Lumen for Parenteral Nutrition Administration Reduce the Risk of Catheter-Related Bloodstream  
17 Infections? A Systematic Literature Review. *J Infus Nurs*. 2018;41:122-30.
- 18 [142] Buchman AL, Opilla M, Kwasny M, Diamantidis TG, Okamoto R. Risk factors for the  
19 development of catheter-related bloodstream infections in patients receiving home parenteral  
20 nutrition. *JPEN J Parenter Enteral Nutr*. 2014;38:744-9.
- 21 [143] Munck A, Malbezin S, Bloch J, Gerardin M, Lebourgeois M, Derelle J, et al. Follow-up of 452  
22 totally implantable vascular devices in cystic fibrosis patients. *Eur Respir J*. 2004;23:430-4.
- 23 [144] Muhlebach S, Franken C, Stanga Z. Practical handling of AIO admixtures - guidelines on  
24 parenteral nutrition, chapter 10. *Ger Med Sci* 2009;7:Doc18.
- 25 [145] Boullata JI, Gilbert K, Sacks G, Labossiere RJ, Crill C, Goday P, et al. A.S.P.E.N. clinical guidelines:  
26 parenteral nutrition ordering, order review, compounding, labeling, and dispensing. *JPEN J Parenter*  
27 *Enteral Nutr*. 2014;38:334-77.
- 28 [146] Pietka M, Szczepanek K, Szybinski P, Klek S. Pp209-Mon Ready-to-Use (Rtu) Bags Versus  
29 Compounded Parenteral Nutrition: Battle for Microbiological Safety. *Clin Nutr*. 2013;32:S199-S200.
- 30 [147] Yu J, Wu G, Tang Y, Ye Y, Zhang Z. Efficacy, Safety, and Preparation of Standardized Parenteral  
31 Nutrition Regimens: Three-Chamber Bags vs Compounded Monobags-A Prospective, Multicenter,  
32 Randomized, Single-Blind Clinical Trial. *Nutr Clin Pract*. 2017;32:545-51.
- 33 [148] Hall JW. Safety, cost, and clinical considerations for the use of premixed parenteral nutrition.  
34 *Nutr Clin Pract*. 2015;30:325-30.
- 35 [149] Berlana D, Sabin P, Rius J, Llop E, Romero R, Marquez E, et al. DSL-006 Cost Analysis of Adult  
36 Parenteral Nutrition Systems: Three-Compartment Bag Versus Customised. *European Journal of*  
37 *Hospital Pharmacy*. 2013;20:A89.2-A.
- 38 [150] Turpin RS, Canada T, Liu FX, Mercaldi CJ, Pontes-Arruda A, Wischmeyer P. Nutrition therapy  
39 cost analysis in the US: pre-mixed multi-chamber bag vs compounded parenteral nutrition. *Appl*  
40 *Health Econ Health Policy*. 2011;9:281-92.
- 41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1 [151] Pichard C, Schwarz G, Frei A, Kyle U, Jolliet P, Morel P, et al. Economic investigation of the use  
2 of three-compartment total parenteral nutrition bag: prospective randomized unblinded controlled  
3 study. *Clin Nutr.* 2000;19:245-51.
- 4 [152] Turpin RS, Solem C, Pontes-Arruda A, Sanon M, Mehta S, Xiaoqing Liu F, et al. The impact of  
5 parenteral nutrition preparation on bloodstream infection risk and costs. *Eur J Clin Nutr.*  
6 2014;68:953-8.
- 7 [153] Liu FX, Mercaldi K, Reynolds MW, Turpin R. Pin50 Methods to Identify and Compare  
8 Bloodstream Infection Rates among Patients Administered Parenteral Nutrition Via Hospital  
9 Compounded Vs. Premixed Multi-Chamber Bags. *Value Health.* 2010;13:A195-A6.
- 10 [154] Beattie C, Allard J, Raman M. Comparison Between Premixed and Compounded Parenteral  
11 Nutrition Solutions in Hospitalized Patients Requiring Parenteral Nutrition. *Nutr Clin Pract.*  
12 2016;31:229-34.
- 13 [155] Milicevic L, Kernan W, Ukleja A. Pp260-Sun Standardized Two-Compartment Parenteral  
14 Nutrition Utilization at a Tertiary Referral Hospital. *Clinical Nutrition Supplements.* 2012;7:127-8.
- 15 [156] Alfonso JE, Berlana D, Ukleja A, Boullata J. Clinical, Ergonomic, and Economic Outcomes With  
16 Multichamber Bags Compared With (Hospital) Pharmacy Compounded Bags and Multibottle  
17 Systems: A Systematic Literature Review. *JPEN J Parenter Enteral Nutr.* 2017;41:1162-77.
- 18 [157] Mühlebach S, Driscoll H, Hardy G. Pharmaceutical aspects of parenteral nutrition support. In:  
19 Sobotka L, Ed, editor. *Basics in Clinical Nutrition 5th ed.* Prague2018. p. 373-400.
- 20 [158] Aeberhard C, Steuer C, Saxer C, Huber A, Stanga Z, Muhlebach S. Physicochemical stability and  
21 compatibility testing of levetiracetam in all-in-one parenteral nutrition admixtures in daily practice.  
22 *Eur J Pharm Sci.* 2017;96:449-55.
- 23 [159] Aeberhard C, Mühlebach S. Parenterale Ernährung – Grundlagen und Durchführung. *Aktuelle*  
24 *Ernährungsmedizin.* 2017;42:53-76.
- 25 [160] White R. Quality parenteral nutrition: an ideal mixed bag. *Proc Nutr Soc.* 2011;70:285-92.
- 26 [161] Kochevar M, Guenter P, Holcombe B, Malone A, Mirtallo J, Directors ABo, et al. ASPEN  
27 statement on parenteral nutrition standardization. *JPEN J Parenter Enteral Nutr.* 2007;31:441-8.
- 28 [162] Mühlebach S. Parenteral Nutrition. In: Ferranti P, Berry E, Jock A, editors. *Encyclopedia of Food*  
29 *Security and Sustainability.* 1 ed: Elsevier; 2018. p. 131-42.
- 30 [163] Ayers P, Adams S, Boullata J, Gervasio J, Holcombe B, Kraft MD, et al. A.S.P.E.N. parenteral  
31 nutrition safety consensus recommendations. *JPEN J Parenter Enteral Nutr.* 2014;38:296-333.
- 32 [164] Pietka M, Watrobska-Swietlikowska D, Szczepanek K, Szybinski P, Sznitowska M, Kłęk S.  
33 Nutritional support teams: the cooperation among physicians and pharmacists helps improve cost-  
34 effectiveness of home parenteral nutrition (HPN). *Nutr Hosp.* 2014;31:251-9.
- 35 [165] Dreesen M, Pironi L, Wanten G, Szczepanek K, Foulon V, Willems L, et al. Outcome Indicators  
36 for Home Parenteral Nutrition Care: Point of View From Adult Patients With Benign Disease. *JPEN J*  
37 *Parenter Enteral Nutr.* 2015;39:828-36.
- 38 [166] Koletzko B, Jauch KW, Verwied-Jorky S, Krohn K, Mittal R. Guidelines on Parenteral Nutrition  
39 from the German Society for Nutritional Medicine (DGEM) - overview. *Ger Med Sci.* 2009;7:Doc27.
- 40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1 [167] British Intestinal Failure Alliance (BIFA). British Intestinal Failure Alliance (BIFA) Position  
2 Statement 2016 Home Parenteral Nutrition (HPN). 2016.
- 3 [168] Konrad D, Roberts S, Corrigan ML, Hamilton C, Steiger E, Kirby DF. Treating Dehydration at  
4 Home Avoids Healthcare Costs Associated With Emergency Department Visits and Hospital  
5 Readmissions for Adult Patients Receiving Home Parenteral Support. *Nutr Clin Pract.* 2017;32:385-  
6 91.
- 7  
8 [169] Laverjat M, Hadj Aissa A, Vanhems P, Bouletreau P, Fouque D, Chambrier C. Chronic  
9 dehydration may impair renal function in patients with chronic intestinal failure on long-term  
10 parenteral nutrition. *Clin Nutr.* 2006;25:75-81.
- 11  
12 [170] Bond A, Teubner A, Taylor M, Cawley C, Abraham A, Dibb M, et al. Assessing the impact of  
13 quality improvement measures on catheter related blood stream infections and catheter salvage:  
14 Experience from a national intestinal failure unit. *Clin Nutr.* 2018;37:2097-101.
- 15  
16 [171] Messing B, Lemann M, Landais P, Gouttebel MC, Gerard-Boncompain M, Saudin F, et al.  
17 Prognosis of patients with nonmalignant chronic intestinal failure receiving long-term home  
18 parenteral nutrition. *Gastroenterology.* 1995;108:1005-10.
- 19  
20 [172] Bischoff SC, Kester L, Meier R, Radziwill R, Schwab D, Thul P. Organisation, regulations,  
21 preparation and logistics of parenteral nutrition in hospitals and homes; the role of the nutrition  
22 support team - Guidelines on Parenteral Nutrition, Chapter 8. *Ger Med Sci.* 2009;7:Doc20.
- 23  
24 [173] Huisman-de Waal G, Versleijen M, van Achterberg T, Jansen JB, Sauerwein H, Schoonhoven L,  
25 et al. Psychosocial complaints are associated with venous access-device related complications in  
26 patients on home parenteral nutrition. *JPEN J Parenter Enteral Nutr.* 2011;35:588-95.
- 27  
28 [174] Huisman-de Waal G, van Achterberg T, Jansen J, Wanten G, Schoonhoven L. 'High-tech' home  
29 care: overview of professional care in patients on home parenteral nutrition and implications for  
30 nursing care. *J Clin Nurs.* 2011;20:2125-34.
- 31  
32 [175] Mantegazza C, La Vela V, Hill S, Koglmeier J. Travelling With Children on Home Parenteral  
33 Nutrition. *J Pediatr Gastroenterol Nutr.* 2016;62:145-9.
- 34  
35 [176] Donabedian A. Evaluating the quality of medical care. *Milbank Q* 2005;83: 691-729.
- 36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



## Figure Legends

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Figure 1. Main structure of the ESPEN practical guideline: Home parenteral nutrition (HPN). The guideline consists of six chapters presented in Figures 2-9. For details see text.

Figure 2. Indications for HPN. In blue letters at the end of each recommendation, three items are indicated: (i) Rx, the original numbering of the recommendations in reference [17], (ii) A or B or O, the grade of evidence, and (iii) x%, the consensus grade.

Figure 3. Central venous accesses device (CVAD) and infusion pump.

Figure 4. Infusion line and catheter site care.

Figure 5. Infusion line and catheter site care (continued).

Figure 6. Nutritional admixtures for HPN.

Figure 7. HPN program monitoring.

Figure 8. HPN management

Figure 9. HPN emergency management

Figure 1




Figure 2

# 1. Indications for HPN




Figure 3

## 2. Central venous accesses device (CVAD) and infusion pump




Figure 4

### 3. Infusion line and catheter site care




Figure 5

### 3. Infusion line and catheter site care




Figure 6

## 4. Nutritional admixtures




Figure 7






Figure 8

## 6. HPN management




Figure 9

## 6. HPN management

